[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 413
1. Ozişik PA, Işikay I, Oruçkaptan H, Söylemezoğlu F, Ozcan OE: Unusual massive spinal metastasis of an intracranial oligodendroglioma. Turk Neurosurg; 2008 Jul;18(3):276-80
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual massive spinal metastasis of an intracranial oligodendroglioma.
  • Herein, we present a case of anaplastic oligodendroglioma with massive spinal metastasis in the first post-operative year without any residual tumor or recurrence in the primary tumor site.
  • Along with the reported literature, our case highlights the importance of periodic radiological evaluation of the spinal canal including the pre- and post-treatment period, in patients with intracerebral oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Seeding. Oligodendroglioma / secondary. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Postoperative Complications

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18814118.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


2. Al-Ali F, Hendon AJ, Liepman MK, Wisniewski JL, Krinock MJ, Beckman K: Oligodendroglioma metastatic to bone marrow. AJNR Am J Neuroradiol; 2005 Oct;26(9):2410-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendroglioma metastatic to bone marrow.
  • We report on a patient with oligodendroglioma metastatic to bone, presenting with pancytopenia and fever 10 years after initial tumor resection.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Brain Neoplasms / pathology. Oligodendroglioma / diagnosis. Oligodendroglioma / secondary
  • [MeSH-minor] Adult. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Thoracic Vertebrae

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16219856.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Nielsen MS, Christensen HC, Kosteljanetz M, Johansen C: Incidence of and survival from oligodendroglioma in Denmark, 1943-2002. Neuro Oncol; 2009 Jun;11(3):311-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of and survival from oligodendroglioma in Denmark, 1943-2002.
  • We established the nationwide, population-based incidence of oligodendroglioma in Denmark during 59 years of monitoring and compared the overall survival of patients with oligodendroglial tumors during the periods 1943-1977 and 1978-2002.
  • On the basis of reports in the Danish Cancer Registry, 1,304 cases of oligodendroglioma were included in the study.
  • In the period 1943-2002, the incidence rate of oligodendroglioma was less than 1 case per 100,000 person-years, but varied somewhat when viewed across isolated periods.
  • The overall incidence of oligodendroglioma showed a relatively stable pattern over nearly 60 years of monitoring.
  • [MeSH-major] Brain Neoplasms / epidemiology. Oligodendroglioma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Child, Preschool. Denmark / epidemiology. Female. Humans. Incidence. Infant. Infant, Newborn. Kaplan-Meier Estimate. Male. Registries. Young Adult

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):479-90 [14585228.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):675-80 [15542975.001]
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):450-5 [14648713.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Ann Neurol. 1988 Apr;23(4):360-4 [3382171.001]
  • [Cites] Int J Epidemiol. 1988 Mar;17(1):44-9 [3384548.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9 [10571199.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 [10598694.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 13):13-8 [11550134.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):61-8 [11550303.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] Surg Neurol. 2002 Aug;58(2):111-7; discussion 117 [12453646.001]
  • [Cites] Neurol India. 2002 Dec;50(4):462-6 [12577096.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):296-303 [12694851.001]
  • [Cites] Cancer. 2003 May 1;97(9):2254-61 [12712480.001]
  • [Cites] Am J Clin Oncol. 2003 Jun;26(3):e60-6 [12796617.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Acta Oncol. 2003;42(3):179-85 [12852693.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):443-56 [14572971.001]
  • [Cites] APMIS. 1989 Jun;97(6):547-55 [2736107.001]
  • [Cites] IARC Sci Publ. 1991;(95):126-58 [1894318.001]
  • [Cites] IARC Sci Publ. 1991;(95):220-36 [1894325.001]
  • [Cites] J Neurosurg. 1992 Mar;76(3):428-34 [1738022.001]
  • [Cites] Neuroepidemiology. 1993;12(5):270-9 [8309502.001]
  • [Cites] Acta Neurol Scand. 1994 Nov;90(5):312-7 [7887130.001]
  • [Cites] J Neurosurg. 1995 Dec;83(6):999-1003 [7490645.001]
  • [Cites] Neurol Clin. 1995 Nov;13(4):861-73 [8584001.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):399-403 [9069313.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1195-202 [9070498.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]
  • [Cites] Dan Med Bull. 1997 Nov;44(5):535-9 [9408738.001]
  • [Cites] Acta Neuropathol. 1998 May;95(5):493-504 [9600596.001]
  • [Cites] Arch Neurol. 1999 Apr;56(4):434-6 [10199331.001]
  • [Cites] J Neurosurg. 2003 Nov;99(5):854-62 [14609165.001]
  • (PMID = 19066344.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2718975
  •  go-up   go-down


Advertisement
4. Nadkarni TD, Menon RK, Desai KI, Goel AH: Cerebellar oligodendroglioma in a young adult. J Clin Neurosci; 2005 Sep;12(7):837-8
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellar oligodendroglioma in a young adult.
  • A rare case of an oligodendroglioma of the cerebellum in an 18-year-old male is presented.
  • [MeSH-major] Cerebellar Neoplasms. Oligodendroglioma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169228.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


5. Yamamoto M, Iwaasa M, Nonaka M, Tsugu H, Nabeshima K, Fukushima T: Efficacy and feasibility of procarbazine, ranimustine and vincristine chemotherapy, and the role of surgical resection in anaplastic oligodendroglioma. Anticancer Res; 2005 Nov-Dec;25(6A):3715-23
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and feasibility of procarbazine, ranimustine and vincristine chemotherapy, and the role of surgical resection in anaplastic oligodendroglioma.
  • The safety, tolerance and preliminary efficacy of a chemotherapy regimen consisting of procarbazine (PCB), ranimustine (MCNU) and vincristine (VCR) were assessed for patients with newly diagnosed supratentorial anaplastic oligodendroglioma.
  • The cycles were repeated every 8 weeks until tumor progression was evident, or for a total of 6 cycles over a 1-year period.
  • However, 3 of the 5 patients showed relapse, with a time to tumor progression (TTP) of 50, 143 and 241 weeks, respectively.
  • Two of these patients received combined treatment with carboplatin, etoposide and recombinant human mutant tumor necrosis factor-alpha at the first relapse.
  • This regimen appeared to be safe and neither neurological toxicity, severe or life-threatening hematological toxicity, nor fatal toxicity (WHO Grade 4) were experienced.
  • However, since the relapse rate was high, a second-line chemotherapy should be developed for anaplastic oligodendroglioma to improve the long-term control of the disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / surgery. Oligodendroglioma / drug therapy. Oligodendroglioma / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Nitrosourea Compounds / administration & dosage. Nitrosourea Compounds / adverse effects. Procarbazine / administration & dosage. Procarbazine / adverse effects. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16302731.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; RYH2T97J77 / ranimustine
  •  go-up   go-down


6. Mut M, Güler-Tezel G, Lopes MB, Bilginer B, Ziyal I, Ozcan OE: Challenging diagnosis: oligodendroglioma versus extraventricular neurocytoma. Clin Neuropathol; 2005 Sep-Oct;24(5):225-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenging diagnosis: oligodendroglioma versus extraventricular neurocytoma.
  • Diagnosis of oligodendroglioma from other clear cell neoplasms of central nervous system (CNS) is still challenging despite advances in neuroradiology and molecular diagnostic tools.
  • Herein, we present a 44-year-old male patient who had a diagnosis of right parietal oligodendroglioma grade II in 1994 which recurred in 2002.
  • He presented with intratumoral hemorrhage and he underwent radical resection of tumor in 2003.
  • Histopathological examination of the recurrent tumor showed anaplastic progression with confusing immunohistochemical (IHC) results; the tumor was positive for NeuN and synaptophysin staining.
  • The question arisen was whether the recurrent tumor was an oligodendroglioma with neuronal differentiation or an extraventricular neurocytoma initially misdiagnosed as oligodendroglioma.
  • Chromosomal analysis revealed 1p/19q deletion, which led to the diagnosis ofanaplastic oligodendroglioma grade III.
  • Accurate diagnosis of oligodendroglioma is crucial due to recent advances and promises in its treatment.
  • Current diagnostic methods of oligodendroglial tumors are discussed in context of differentiating oligodendrogliomas from other clear cell neoplasms of CNS, especially from extraventricular neurocytomas.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neurocytoma / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Male. Nerve Tissue Proteins / biosynthesis. Synaptophysin / biosynthesis

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167546.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Synaptophysin
  •  go-up   go-down


7. Kang SG, Kim JH, Nam DH, Park K: Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy. Neurol Med Chir (Tokyo); 2005 May;45(5):232-8; discussion 238-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and radiological prognostic factors of anaplastic oligodendroglioma treated by combined therapy.
  • The clinical and radiological prognostic factors were investigated in 32 patients with newly diagnosed anaplastic oligodendroglioma treated by combined therapy using surgery, postoperative radiation therapy, and adjuvant chemotherapy between September 1994 and December 2002.
  • Survival analysis showed that younger age, absence of preoperative headache, good postoperative Karnofsky Performance Status (KPS) score (>or=80), and relatively small tumor volume (<50 cm3) were predictors for longer survival in univariate analysis (p<0.05).
  • [MeSH-major] Brain Neoplasms / radiography. Brain Neoplasms / therapy. Oligodendroglioma / radiography. Oligodendroglioma / therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15914962.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


8. Merrell R, Nabors LB, Perry A, Palmer CA: 1p/19q chromosome deletions in metastatic oligodendroglioma. J Neurooncol; 2006 Nov;80(2):203-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 1p/19q chromosome deletions in metastatic oligodendroglioma.
  • Extracranial metastasis of primary brain tumors is a rare phenomenon.
  • Of the few cases reported of metastatic oligodendroglioma, only two have evaluated genetic alterations, specifically deletions of chromosomes 1p and 19q.
  • Herein, we report two additional patients with metastatic anaplastic oligodendroglioma to bone, both followed until death.
  • Although the bone metastasis was non-informative, the primary intracranial tumor revealed codeletions of the 1p and 19q chromosomal arms, commonly recognized as the genetically favorable profile of oligodendrogliomas.
  • Along with the reported literature, our data suggest that despite their generally favorable behavioral profiles, oligodendroglial tumors with 1p/19q deletions may be more prone to metastasis as they progress.
  • [MeSH-major] Bone Marrow Neoplasms / genetics. Bone Marrow Neoplasms / secondary. Bone Neoplasms / genetics. Bone Neoplasms / secondary. Brain Neoplasms / pathology. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Oligodendroglioma / genetics. Oligodendroglioma / secondary. Spinal Neoplasms / genetics. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Fatal Outcome. Female. Humans. In Situ Hybridization. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710746.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


9. El-Hateer H, Souhami L, Roberge D, Maestro RD, Leblanc R, Eldebawy E, Muanza T, Melançon D, Kavan P, Guiot MC: Low-grade oligodendroglioma: an indolent but incurable disease? Clinical article. J Neurosurg; 2009 Aug;111(2):265-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade oligodendroglioma: an indolent but incurable disease? Clinical article.
  • OBJECT: The authors reviewed their institutional experience with pure low-grade oligodendroglioma (LGO), correlating outcomes with several variables of possible prognostic values.
  • Demographic characteristics; the nature and duration of presenting symptoms; baseline neurological function; extent of resection; Karnofsky Performance Scale score; preoperative radiological findings including tumor size, location, and absence/presence of enhancement; and pathological data including chromosome arms 1p/19q codeletion and O-methylguanine-DNA methyltransferase promoter gene methylation status were all compiled.
  • The timing and dose of radio- and/or chemotherapy, date of tumor progression, pathological finding at disease progression, treatment at time of disease progression, and status at the last follow-up were also recorded.
  • [MeSH-major] Brain Neoplasms / mortality. Oligodendroglioma / mortality
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19284232.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Nataf F, Koziak M, Ricci AC, Varlet P, Devaux B, Beuvon F, Roujeau T, Page P, Cioloca C, Turak B, Schlienger M, Touboul E, Haie-Meder C, Vannetzel JM, Dhermain F, Honnorat J, Jouvet A, De Saint-Pierre G, Daumas-Duport C, Bret P, Roux FX: [Results of the Sainte-Anne - Lyons series of 318 oligodendroglioma in adults]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):329-51
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of the Sainte-Anne - Lyons series of 318 oligodendroglioma in adults].
  • [Transliterated title] Résultats de la série Sainte-Anne - Lyon de 318 oligodendrogliomes intracrâniens de l'adulte.
  • INTRODUCTION: Incidence of cerebral oligodendrogliomas is increasing because of better recognition made possible by improved classifications.
  • PATIENTS AND METHODS: A retrospective series of 318 adult patients with oligodendroglioma (OLG) treated at Hôpital Sainte-Anne, Paris (SA) and Hôpital Neurologique, Lyons (L) between 1984 and 2003 was analyzed: 182 grade A OLG (SA + L), 136 grade B among which a homogenous series of 98 (SA) were included.
  • For grade A: age at diagnosis ranged from 21 to 70 (mean: 41), sex ratio was 1.28.
  • For grade B: age at diagnosis ranged from 12 to 75 (mean: 45.5), sex-ratio was 1.58.
  • The most frequent locations were: frontal, insular and central for both A and B.
  • Mean size was 55 mm for grade A, 62 mm for B.
  • No tumor was enhanced on imaging (CT/MRI) in grade A, all but 7 in grade B.
  • Radiotherapy was performed in 76.9% of grade A, and 91% of B patients, in the immediate postoperative period for 71% A and 82.7% B.
  • Chemotherapy was delivered for 36% of grade A (in the event of transformation to grade B or failure of radiotherapy) and 67.5% of B patients.
  • Among grade A tumors, 38% transformed into grade B within a mean delay of 51 months with a mean follow-up of 78 months.
  • RESULTS: Median survival was 136 months for grade A and 52 for grade B.
  • Survival at 5, 10 and 15 was 75.5%, 51% and 22.4% for grade A vs 45.2%, 31.3% and 0% for grade B respectively.
  • In univariate and multivariate analysis, grade A survival was associated with age at diagnosis, tumor size, large removal and response to radiotherapy.
  • Grade B survival was associated with age at diagnosis, wide removal and sharply defined limits of the tumor on imaging.
  • It shows that OLG are heterogeneous tumors even in each grade (A and B).
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Staging / methods. Oligodendroglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Epilepsy / diagnosis. Epilepsy / etiology. Female. Frontal Lobe / pathology. Frontal Lobe / surgery. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292177.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Kleinschmidt S, Herzog K, Krüger L, Kuchelmeister K, Wohlsein P: Diffuse intracranial oligodendroglioma in a cow. J Comp Pathol; 2009 Jan;140(1):72-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse intracranial oligodendroglioma in a cow.
  • This report describes the clinical, morphological and immunohistochemical findings in an adult cow with cerebral oligodendroglioma.
  • This is the first report describing a diffuse, cerebral oligodendroglioma in a cow.
  • [MeSH-major] Brain Neoplasms / veterinary. Cattle Diseases / diagnosis. Oligodendroglioma / veterinary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064271.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / S100 Proteins; 0 / tau Proteins
  •  go-up   go-down


12. Guppy KH, Akins PT, Moes GS, Prados MD: Spinal cord oligodendroglioma with 1p and 19q deletions presenting with cerebral oligodendrogliomatosis. J Neurosurg Spine; 2009 Jun;10(6):557-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord oligodendroglioma with 1p and 19q deletions presenting with cerebral oligodendrogliomatosis.
  • Oligodendroglioma of the spinal cord is a rare tumor that most often presents with spinal cord symptoms.
  • The authors present a case of spinal cord oligodendroglioma that was associated with cerebral rather than spinal cord symptoms.
  • Magnetic resonance imaging of the brain showed meningeal enhancement.
  • The patient underwent a craniotomy with biopsies of the meninges and brain.
  • The biopsy findings revealed an abnormal arachnoid thickening without tumor cells.
  • Cerebrospinal fluid cytological findings were negative for tumor cells or infection.
  • Biopsy of the cord lesion with partial resection showed a WHO Grade II oligodendroglioma with 1p and 19q deletions determined by fluorescence in situ hybridization.
  • Neurooncological treatment with tumor radiation and temozolomide (Temodor) resulted in improvement in radiographic findings, symptoms, and long-term survival.
  • This paper presents an extensive review of the literature, which revealed only 2 other reported cases of cerebral symptoms in adults that preceded spinal cord symptoms in a patient with oligodendroglioma of the spinal cord.
  • It is also the first reported case of oligodendrogliomatosis due to a cervical spinal cord oligodendroglioma with 1p and 19q deletions.
  • [MeSH-major] Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Gene Deletion. Oligodendroglioma / genetics. Spinal Cord Neoplasms / genetics
  • [MeSH-minor] Adult. Cerebrospinal Fluid Shunts. Female. Humans. Hydrocephalus / pathology. Hydrocephalus / surgery. Magnetic Resonance Imaging. Reoperation

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19558288.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Desjardins A, Reardon DA, Gururangan S, Peters K, Threatt S, Friedman A, Friedman H, Vredenburgh J: Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG). J Clin Oncol; 2009 May 20;27(15_suppl):e13004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG).
  • METHODS: Eligibility included: adult patients with stable or recurrent MG (GBM, anaplastic astrocytoma [AA], anaplastic oligodendroglioma [AO]) previously treated with radiation therapy (RT) and with or without chemotherapy; interval of at least two weeks between prior RT, or four weeks between prior chemotherapy; Karnofsky ≥ 60%; and adequate hematologic, renal and liver function.
  • Dose-limiting toxicities were: deep venous thrombosis (1 grade 3); nausea and vomiting (1 grade 3); diarrhea (1 grade 3); elevated ALT (1 grade 3); elevated creatinine (1 grade 3); and fatigue (1 grade 3).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962751.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Zada G, McNatt SA, Gonzalez-Gomez I, McComb JG: Anaplastic intraventricular oligodendroglioma: case report and review of the literature. Surg Neurol; 2009 Jun;71(6):693-700
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic intraventricular oligodendroglioma: case report and review of the literature.
  • BACKGROUND: Intraventricular oligodendroglioma remains a rare diagnosis, with high-grade/anaplastic IVO being an even rarer subtype.
  • These lesions vary in regard to tumor grading and clinical presentation, as compared with their intraparenchymal counterparts.
  • A case report and review of the previous literature regarding IVO and tumor grading were conducted.
  • CASE DESCRIPTION: A case report of a patient with an anaplastic oligodendroglioma confined entirely within the ventricular system is presented.
  • Only 2 previous case reports of high-grade/anaplastic IVO were identified.
  • Adjuvant therapies may differ significantly according to the tumor grade and molecular subtype.
  • CONCLUSIONS: Intraventricular oligodendroglioma remains an infrequently encountered lesion, yet is usually found to be low grade at the time of surgery.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricle Neoplasms / surgery. Oligodendroglioma / diagnosis. Oligodendroglioma / surgery
  • [MeSH-minor] Female. Humans. Young Adult

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18291495.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


15. Opris I, Ducrotoy V, Bossut J, Lamy A, Sabourin JC: Oligodendroglioma arising in an ovarian mature cystic teratoma. Int J Gynecol Pathol; 2009 Jul;28(4):367-71
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendroglioma arising in an ovarian mature cystic teratoma.
  • SUMMARY: We describe a case of oligodendroglioma arising in an ovarian mature cystic teratoma associated with a loss of heterozygosity on the long arm of chromosomes 19 and 10.
  • These findings were consistent with a low-grade oligodendroglioma arising in a mature ovarian cystic teratoma.
  • Reverse transcription-polymerase chain reaction analysis showed a characterized loss of heterozygosity occurring in tumor DNA on chromosomes 10q and 19q13.
  • [MeSH-major] Neoplasms, Multiple Primary / pathology. Oligodendroglioma / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Humans. Immunohistochemistry. Loss of Heterozygosity. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483626.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Xiong J, Liu Y, Li C, Zhu JJ, Ye ZR, Mao Y, Wang Y: [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma]. Zhonghua Bing Li Xue Za Zhi; 2009 Jul;38(7):445-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma].
  • OBJECTIVE: To study the status of loss of heterozygosity (LOH) of chromosome 1p/19q and p53 protein expression in oligodendroglioma, as compared to astrocytoma.
  • METHODS: One hundred and ninety-one cases of glioma of different histologic types and grades, including 116 cases of low-grade of oligodendroglioma (86 paraffin-embedded and 30 fresh tissues), 45 cases of anaplastic oligodendroglioma (all paraffin-embedded tissues) and 30 cases of astrocytoma of various grades (all paraffin-embedded tissues), were enrolled into the study.
  • RESULTS: The rates of 1p loss, 19q loss and 1p/19q loss were 69.8%, 64%, and 57.0% respectively in the 86 paraffin-embedded low-grade oligodendroglioma samples, as compared to 71.1%, 60.0% and 55.6% respectively in the 45 paraffin-embedded anaplastic oligodendroglioma samples.
  • There was no difference of LOH of 1p/19q between low-grade oligodendroglioma and anaplastic oligodendroglioma (P>0.05).
  • In the 30 cases of low-grade oligodendroglioma with fresh tissues available, the rates of 1p loss, 19q loss and 1p/19q loss were 70.0%, 63.3% and 60.0% respectively.
  • In the 30 cases of astrocytoma, the rates of 1p loss, 19q loss and 1p/19q loss were 23.3%, 33.3% and 20.0% respectively, which were significantly less than those in oligodendroglioma (P<0.05).
  • The expression of p53 protein was significantly lower in low-grade oligodendroglioma (8.1%) than in anaplastic oligodendroglioma (31.1%, P=0.007).
  • The expression of p53 protein in oligodendroglioma was also lower than in astrocytoma (P=0.001).
  • Furthermore, p53 protein expression negatively correlated with 1p/19q loss in anaplastic oligodendroglioma (P<0.05).
  • Oligodendroglioma demonstrates a higher frequency of LOH of chromosome 1p/19q and lower expression of p53 protein than astrocytoma.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Loss of Heterozygosity. Oligodendroglioma / genetics. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Astrocytoma / metabolism. Child. Female. Humans. Male. Middle Aged. Paraffin Embedding. Young Adult

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781190.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


17. Takeuchi H, Kubota T, Kitai R, Matsuda K, Hashimoto N, Sato K: Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component. J Neurooncol; 2009 Jan;91(1):33-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component.
  • We encountered seven cases of MGNT with oligodendroglioma-like component and investigated alternations of chromosome 1p and 19q in these tumors.
  • We undertook a molecular cytogenetic study of tumor specimens obtained from seven patients using fluorescence in situ hybridization (FISH) with DNA probes mapping to chromosome 1p36, 1q25, 19p13 and 19q13.
  • Histologically, these tumors resembled anaplastic oligodendroglioma.
  • Immunohistochemically, tumor cells were immunoreactive for synaptophysin (7/7), neurofilament (6/7), beta-tubulin (5/7), chromogranin A (4/7), NeuN (2/7) and GFAP (7/7).
  • 1p and 19q deletions were present in MGNT, especially those with oligodendroglial components.
  • We suggest that the oligodendroglial-like feature was associated with not only 1p or 19q loss but also differentiation along neuronal cell lines as a factor of favorable prognosis in glial tumors.
  • It is inappropriate to make a diagnosis of oligodendroglioma based only on morphological resemblance to oligodendroglia.
  • [MeSH-major] Brain Neoplasms / metabolism. Chromosome Deletion. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Oligodendroglioma / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Nerve Tissue Proteins / metabolism. Oligodendroglia / metabolism. Oligodendroglia / pathology

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18781279.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Nerve Tissue Proteins
  •  go-up   go-down


18. Ramirez C, Delrieu O, Mineo JF, Paradot G, Allaoui M, Dubois F, Blond S: Intracranial dissemination of primary spinal cord anaplastic oligodendroglioma. Eur J Neurol; 2007 May;14(5):578-80
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial dissemination of primary spinal cord anaplastic oligodendroglioma.
  • We report the first case of a 22-year-old man, with a previously neurosurgically treated intramedullary anaplastic oligodendroglioma (World Health Organization grade III), who developed 19 months later two histologically proven intracranial metastases.
  • [MeSH-major] Brain Neoplasms / secondary. Neoplasm Metastasis / physiopathology. Oligodendroglioma / secondary. Spinal Cord Neoplasms / pathology. Subarachnoid Space / physiopathology
  • [MeSH-minor] Adult. Cerebellar Neoplasms / secondary. Fatal Outcome. Humans. Hydrocephalus / etiology. Hydrocephalus / physiopathology. Hydrocephalus / therapy. Lateral Ventricles / pathology. Lateral Ventricles / physiopathology. Male. Neurosurgical Procedures / adverse effects

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17437621.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Fayeye O, Sankaran V, Sherlala K, Choksey M: Oligodendroglioma presenting with intradural spinal metastases: an unusual cause of cauda equina syndrome. J Clin Neurosci; 2010 Feb;17(2):265-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendroglioma presenting with intradural spinal metastases: an unusual cause of cauda equina syndrome.
  • We report a 37-year-old man with a primary intracranial oligodendroglioma presenting later with symptomatic multiple cerebrospinal fluid (CSF) intradural drop spinal metastases.
  • Initial histology demonstrated World Health Organization (WHO) grade 2 oligodendroglioma.
  • Histology showed anaplastic transformation to a WHO grade 3 oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / pathology. Dura Mater / pathology. Lumbar Vertebrae / pathology. Meningeal Carcinomatosis / secondary. Meningeal Neoplasms / secondary. Oligodendroglioma / secondary. Polyradiculopathy / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Arachnoid / pathology. Arachnoid / physiopathology. Cauda Equina / pathology. Cauda Equina / physiopathology. Craniotomy. Fatal Outcome. Frontal Lobe / pathology. Frontal Lobe / physiopathology. Hemiplegia / etiology. Hemiplegia / physiopathology. Humans. Magnetic Resonance Imaging. Male. Palliative Care. Radiotherapy. Seizures / etiology. Spinal Cord Neoplasms / secondary. Treatment Failure. Urinary Bladder, Neurogenic / etiology

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2009. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20042338.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


20. Roldán G, Scott J, George D, Parney I, Easaw J, Cairncross G, Forsyth P, Yan E: Leptomeningeal disease from oligodendroglioma: clinical and molecular analysis. Can J Neurol Sci; 2008 May;35(2):204-9
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal disease from oligodendroglioma: clinical and molecular analysis.
  • A long surviving case led us to review our experience with LMD in patients with oligodendrogliomas.
  • Patients with both oligodendroglial tumors and LMD were identified.
  • RESULTS: Seven out of 145 patients with oligodendroglioma were diagnosed with LMD.
  • Median age at tumor diagnosis was 41 years (range, 28-50).
  • None had radiographic or pathological evidence of leptomeningeal or subependymal tumor at initial diagnosis.
  • Most patients had pure anaplastic oligodendrogliomas (4/7); 6/7 had 1p/19q co-deletion.
  • CONCLUSIONS: Leptomeningeal disease is a complication of oligodendroglioma that may occur preferentially in long surviving patients with 1p/19q co-deletion.
  • Leptomeningeal disease in patients with oligodendrogliomas appears to be relatively indolent which may have implications for their treatment and be related to 1p/19q status.
  • [MeSH-major] Chromosome Aberrations. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Meningeal Neoplasms / genetics. Meninges / pathology. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Longitudinal Studies. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574935.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


21. Holmlund C, Haapasalo H, Yi W, Raheem O, Brännström T, Bragge H, Henriksson R, Hedman H: Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology; 2009 Jun;29(3):242-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival.
  • Of these, LRIG1 negatively regulates growth factor signaling and is implicated as a tumor suppressor in certain malignancies.
  • The role of LRIG proteins in oligodendroglioma has not previously been studied.
  • Here we used immunohistochemistry to analyze the expression of the LRIG proteins in 63 oligodendroglial tumors, and evaluated possible associations between LRIG protein expression and clinicopathological parameters.
  • Notably, cytoplasmic LRIG2 expression was found to be an independent prognostic factor associated with poor oligodendroglioma patient survival.
  • This is the first report of an LRIG protein showing a negative effect on survival, suggesting that LRIG2 might have a function different from that of LRIG1, and possibly contributing to the etiology of oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Cytoplasm / metabolism. Membrane Glycoproteins / metabolism. Oligodendroglioma / diagnosis. Oligodendroglioma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Nucleus / metabolism. Female. Humans. Kaplan-Meier Estimate. Male. Membrane Proteins / metabolism. Middle Aged. Neoplasm Staging. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18992012.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / LRIG1 protein, human; 0 / LRIG2 protein, human; 0 / LRIG3 protein, human; 0 / Membrane Glycoproteins; 0 / Membrane Proteins
  •  go-up   go-down


22. Inagawa H, Ishizawa K, Hirose T: Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma. Acta Cytol; 2007 Nov-Dec;51(6):900-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • OBJECTIVE: To evaluate the usefulness of intraoperative cytology for differential diagnoses of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • STUDY DESIGN: Qualitative analysis of cytologic features of the 3 brain tumors was conducted using intraoperative touch or squash preparations that were stained with the Papanicolaou method, targeting the cellular density, cytoplasmic and nuclear profiles and blood vessel morphology.
  • In addition, we attempted a computer-assisted image analysis of tumor cell nuclei and compared the results with qualitative observations.
  • Oligodendrogliomas were characterized by small, round nuclei and a fine, delicate capillary network.
  • In both tumors of a higher grade, anaplastic large nuclei and proliferating endothelial cells were noted.
  • Oligoastrocytomas showed combined cytologic profiles of astrocytomas and oligodendrogliomas.
  • Quantitative studies suggested that nuclei of oligodendroglial tumors were significantly rounder than those of astrocytomas.
  • CONCLUSION; Cytologic evaluation using touch or squash preparations is of great help for intraoperative differential diagnosis of astrocytoma, oligodendroglioma and oligoastrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Cytodiagnosis / methods. Oligodendroglioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Count. Cell Nucleus / pathology. Child. Child, Preschool. Cytoplasm / pathology. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Intraoperative Period. Male. Middle Aged


23. Klysik M, Gavito J, Boman D, Miranda RN, Hanbali F, De Las Casas LE: Intraoperative imprint cytology of central neurocytoma: The great oligodendroglioma mimicker. Diagn Cytopathol; 2010 Mar;38(3):202-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative imprint cytology of central neurocytoma: The great oligodendroglioma mimicker.
  • Intraoperative cytologic evaluation of brain tumors has been used either to render a preliminary interpretation or more often as a complement to frozen section examination.
  • Central neurocytoma is a intraventricular neoplasm, typically located in the region of the foramen of Monro, affecting mostly young to middle age adults.
  • Histologically, central neurocytomas are characterized by monotonous cells with round nuclei and neuronal differentiation within a rich capillary network.
  • Their distinction during intraoperative consultations from oligodendroglioma, ependymoma (mainly clear cell ependymoma), and non-Hodgkin lymphoma can be a diagnostic challenge.
  • We report a case of a 19-year-old female with an intraventricular tumor where imprint cytology preparations were crucial for the intraoperative diagnosis of central neurocytoma.
  • Imprint cytology preparations show a round cell neoplasm associated with neuropil clumps and short straight capillaries admixed with tumor cell clusters.
  • To the best of our knowledge, only a few cases describing the cytologic findings of central neurocytomas have been reported in the medical literature.
  • [MeSH-major] Brain Neoplasms / pathology. Cytodiagnosis / methods. Neurocytoma / pathology. Oligodendroglioma / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Ependymoma / diagnosis. Female. Humans. Immunoenzyme Techniques. Intraoperative Period. Lymphoma, Non-Hodgkin / diagnosis. Magnetic Resonance Imaging. Tomography, X-Ray Computed. Treatment Outcome. Young Adult


24. Chamberlain MC, Glantz MJ: CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. J Neurooncol; 2008 Sep;89(2):231-8
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
  • OBJECTIVE: A Phase II study of CPT-11 in adults with recurrent, temozolomide (TMZ)-refractory, 1p19q co-deleted, anaplastic oligodendroglioma (AO) with a primary objective of determining 6-month progression free survival (PFS).
  • CPT-11 related toxicity included diarrhea (14 patients; 4 grade 3), neutropenia (8; 4 grade 3), fatigue (12; 3 grade 3), and delayed nausea/vomiting (12; 3 grade 3).
  • Time to tumor progression ranged from 2 to 13.5 months (median: 4.5 months).
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / adverse effects. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Female. Humans. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18480965.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


25. Combs SE, Schulz-Ertner D, Thilmann C, Edler L, Debus J: Fractionated stereotactic radiation therapy in the management of primary oligodendroglioma and oligoastrocytoma. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):797-802
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated stereotactic radiation therapy in the management of primary oligodendroglioma and oligoastrocytoma.
  • PURPOSE: To retrospectively analyze the outcomes and benefits from radiation therapy (RT) as a component of multimodal treatment for oligodendroglioma and oligoastrocytoma, assessing local control and survival rates and evaluating prognostic factors.
  • METHODS AND MATERIALS: We retrospectively reviewed 56 adult patients with supratentorial oligodendroglioma or oligoastrocytoma treated at our institution from January 1990 to December 2003 with fractionated stereotactic RT (FSRT).
  • With regard to histology, overall survival rates in the World Health Organization (WHO) Grade II group were 89% and 74% at 5 and 10 years, respectively.
  • In patients with WHO Grade III tumors, overall survival rates at 5 and 10 years were 69% and 46%, respectively.
  • CONCLUSIONS: Commonly, conventional conformal RT is applied in the treatment of brain tumors.
  • In FSRT, the tumor volume can be irradiated with high doses, sparing volume of normal brain tissue.
  • Fractionated stereotactic RT can therefore be implemented as an effective and safe modality in the therapy of primary oligodendroglioma and oligoastrocytoma.
  • [MeSH-major] Astrocytoma / surgery. Oligodendroglioma / surgery. Stereotaxic Techniques. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adult. Dose Fractionation. Female. Humans. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936562.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Hamlat A, Saikali S, Chaperon J, Le Calve M, Gedouin D, Ben-Hassel M, Guegan Y: Oligodendroglioma: clinical study and survival analysis correlated with chromosomal anomalies. Neurosurg Focus; 2005 Nov;19(5):E15
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendroglioma: clinical study and survival analysis correlated with chromosomal anomalies.
  • OBJECT: Demonstration of the loss of chromosomes 1p and 19q in the presence of a brain neoplasm marks the emergence of genotype as a prognostic indicator.
  • The authors report gene expression data for oligodendroglioma and correlate genotype with response to therapy.
  • METHODS: Eighty-seven cases of supratentorial oligodendroglioma were selected from 145 cases treated in a single center between January 1990 and December 2001.
  • Three molecular subtypes emerged: oligodendroglioma with 1p and 19q deletions, oligodendroglioma demonstrating polysomia and a lack of meaningful response to radiotherapy or chemotherapy, and oligodendroglioma with no 1p-9q deletion in which partial response was seen.
  • CONCLUSIONS: According to our data, oligodendrogliomas could be divided into three molecular subtypes.
  • Although chemotherapy seems efficient for managing this tumor, additional studies should be conducted to compare the efficacy of radiotherapy and chemotherapy.
  • [MeSH-major] Chromosome Aberrations. Oligodendroglioma / epidemiology. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Confidence Intervals. Female. Gene Deletion. Gene Expression Regulation, Neoplastic / genetics. Humans. Male. Middle Aged. Multivariate Analysis. Odds Ratio. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398465.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Sunyach MP, Jouvet A, Perol D, Jouanneau E, Guyotat J, Gignoux L, Carrie C, Frappaz D: Role of exclusive chemotherapy as first line treatment in oligodendroglioma. J Neurooncol; 2007 Dec;85(3):319-28
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of exclusive chemotherapy as first line treatment in oligodendroglioma.
  • PURPOSE: The optimal therapy of oligodendrogliomas remains uncertain.
  • METHODS AND MATERIALS: Among 89 patients treated for oligodendrogliomas at the Centre Léon Bérard of Lyon from 1982 to 1999, 59 patients fitted inclusion criteria, having had centrally reviewed pure oligodendroglioma requiring treatment.
  • According to the WHO's classification 35 patients had Grade III and 24, Grade II oligodendrogliomas.
  • CONCLUSION: Front-line exclusive chemotherapy results in prolonged OS in patients with confirmed pure oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Oligodendroglioma / drug therapy. Oligodendroglioma / radiotherapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Frontal Lobe / pathology. Humans. Male. Middle Aged. Retrospective Studies. Statistics, Nonparametric. Treatment Outcome

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurooncol. 2008 Feb;86(3):361-2 [17710374.001]
  • (PMID = 17568995.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


28. Chamberlain MC, Johnston S: Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma. Cancer; 2009 Apr 15;115(8):1734-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
  • BACKGROUND: A retrospective evaluation of single agent bevacizumab was carried out in adults with recurrent alkylator-refractory 1p19q codeleted anaplastic oligodendrogliomas (AO) with an objective of determining progression-free survival (PFS).
  • Bevacizumab-related toxicity included fatigue (14 patients; 4 grade 3), leukopenia (9; 1 grade 3), anemia (5; 0 grade 3), hypertension (5; 1 grade 3), deep vein thrombosis (4; 1 grade 3), and wound dehiscence (2; 1 grade 3).
  • Time to tumor progression ranged from 1 to 18 months (median, 6.75 months).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Bevacizumab. Chromosomes, Human, Pair 1. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19197992.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Alkylating; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


29. Ozyigit G, Onal C, Gurkaynak M, Soylemezoglu F, Zorlu F: Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma: single institutional review of 88 patients. J Neurooncol; 2005 Nov;75(2):189-93
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative radiotherapy and chemotherapy in the management of oligodendroglioma: single institutional review of 88 patients.
  • We retrospectively evaluate the prognostic factors affecting the local control, survival and the potential role of chemotherapy in the management of patients with oligodendroglioma.
  • The median RT dose was 54.8 +/- 2.58 Gy for low-grade tumors, and 58.7 +/- 2.46 Gy for high-grade tumors.
  • High grade tumors had significantly lower overall survival rate.
  • Age, presence of motor deficit at diagnosis and histological grade were found have a significant impact on progression-free survival.
  • The 5-year overall and progression free survival rates of patients with high-grade tumors were 69%, 51% and 74%, 68% for chemotherapy and no-chemotherapy group, respectively (P=0.9 for OS, P=0.3 for PFS).
  • Chemotherapy given after postoperative radiotherapy in patients with oligodendroglioma did not improve survival in this retrospective study.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Oligodendroglioma / diagnosis. Oligodendroglioma / drug therapy. Oligodendroglioma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132506.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


30. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmström PO, Collette L, Piérart M, Mirimanoff R, Karim AB, EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet; 2005 Sep 17-23;366(9490):985-90
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial.
  • BACKGROUND: Postoperative policies of "wait-and-see" and radiotherapy for low-grade glioma are poorly defined.
  • In 1986 the EORTC Radiotherapy and Brain Tumor Groups initiated a prospective trial to compare early radiotherapy with delayed radiotherapy.
  • Patients with low-grade astrocytoma, oligodendroglioma, mixed oligoastrocytoma, and incompletely resected pilocytic astrocytoma, with a WHO performance status 0-2 were eligible.
  • Radiotherapy could be deferred for patients with low-grade glioma who are in a good condition, provided they are carefully monitored.
  • [MeSH-major] Astrocytoma / radiotherapy. Central Nervous System Neoplasms / radiotherapy. Oligodendroglioma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Disease-Free Survival. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Survival Rate

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2005 Dec;6(12):921; author reply 922 [16321759.001]
  • [ErratumIn] Lancet. 2006 Jun 3;367(9525):1818
  • (PMID = 16168780.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10 CA11488-; United States / NCI NIH HHS / CA / 5U10 CA11488-16
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


31. Uzuka T, Kakita A, Inenaga C, Takahashi H, Tanaka R, Takahashi H: Frontal anaplastic oligodendroglioma showing multi-organ metastases after a long clinical course. Case report. Neurol Med Chir (Tokyo); 2007 Apr;47(4):174-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontal anaplastic oligodendroglioma showing multi-organ metastases after a long clinical course. Case report.
  • A 17-year-old woman presented with an anaplastic oligodendroglioma manifesting as generalized seizure.
  • Neuroimaging studies revealed a right frontal tumor.
  • Histological examinations of biopsy specimens revealed that the tumor was oligodendroglial in nature.
  • The final diagnosis was anaplastic oligodendroglioma.
  • Despite irradiation, combination chemotherapy, and interstitial hyperthermia, the tumor grew rapidly but was confined to the cavity created by previous removal operations.
  • At autopsy, generalized metastases from the tumor were identified at various sites, including the dura mater covering the frontal lobes and thoracic cord, cavernous sinus, tuberculum sellae, spleen, liver, pancreas, lungs, paratracheal lymph nodes, vertebral bodies, ribs, sternum, pelvis, dorsal root ganglia, and iliopsoas muscle.
  • This rare case of cerebral anaplastic oligodendroglioma developed in adolescence, and rapid hematogenous spread of the glioma cells into the systemic organs occurred after a relatively long clinical course.
  • [MeSH-major] Brain Neoplasms / pathology. Frontal Lobe. Oligodendroglioma / secondary
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Time Factors

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17457022.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Ngo L, Nei M, Glass J: Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma. Epilepsia; 2006 Jul;47(7):1237-8
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma.
  • A 40-year-old man with a left frontotemporal grade II oligodendroglioma developed seizures that were refractory to 14 antiepileptic medications, the ketogenic diet, and epilepsy surgery.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Epilepsy / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Anticonvulsants / therapeutic use. Comorbidity. Drug Resistance. Humans. Magnetic Resonance Imaging. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886989.001).
  • [ISSN] 0013-9580
  • [Journal-full-title] Epilepsia
  • [ISO-abbreviation] Epilepsia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


33. Kocaeli H, Yakut T, Bekar A, Taşkapilioğlu O, Tolunay S: Glioblastomatous recurrence of oligodendroglioma remote from the original site: a case report. Surg Neurol; 2006 Dec;66(6):627-30; discussion 630-1
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastomatous recurrence of oligodendroglioma remote from the original site: a case report.
  • BACKGROUND: As in all diffuse gliomas, recurrence is an inherent feature of oligodendrogliomas, either as the same or higher grade neoplasm at the primary site.
  • The rate of remote recurrence after surgery for the primary tumor cannot be estimated from the scarce literature, but delayed treatment of the primary tumor and genetic alterations may be associated with this phenomenon.
  • A magnetic resonance imaging scan disclosed a right frontal mass lesion showing features of a low-grade glioma for which he refused any treatment.
  • Seven months after diagnosis upon uncontrollable seizures, he underwent a stereotactic biopsy, which was followed by a right frontal craniotomy, both of which confirmed the lesion as a grade 2 oligodendroglioma.
  • CONCLUSION: Recurrence of a frontal lobe oligodendroglioma remote from the primary site as a GBM is a rare occurrence.
  • As the genetic analysis suggests, conversion of oligodendroglioma to GBM may be associated with gain of chromosome 7, loss of chromosome 10, and other genetic markers that may represent late events in the oncogenesis of oligodendroglial tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Frontal Lobe / pathology. Glioblastoma / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Chromosome Deletion. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 7 / genetics. Craniotomy. Humans. Magnetic Resonance Imaging. Male. Monosomy / diagnosis. Monosomy / genetics. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local. Radiosurgery / instrumentation. Seizures / diagnosis. Seizures / etiology. Trisomy / diagnosis. Trisomy / genetics

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145331.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Kanner AA, Staugaitis SM, Castilla EA, Chernova O, Prayson RA, Vogelbaum MA, Stevens G, Peereboom D, Suh J, Lee SY, Tubbs RR, Barnett GH: The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J Neurosurg; 2006 Apr;104(4):542-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making.
  • OBJECT: Oligodendrogliomas are rare primary brain tumors.
  • Allelic loss of chromosome arms 1p and 19q is found in a substantial subpopulation of tumors with an oligodendroglioma phenotype.
  • Anaplastic oligodendrogliomas with allelic loss of 1p have been associated with chemosensitivity and a longer patient survival period.
  • METHODS: Oligodendroglial neoplasms were studied using fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissue specimens; reference and target probe sets were used to map the telomeric regions of 1p and 19q.
  • This included 63 patients (65.6%) with World Health Organization (WHO) Grade II oligodendroglioma, 22 (23%) with Grade III oligodendroglioma, and 11 (11.4%) with mixed oligoastrocytoma.
  • Analysis of 1p in patients with pure oligodendroglioma revealed a loss of 1p in 42 patients (49.4%).
  • Patients with oligodendroglioma in whom a loss of 1p was present fared significantly better, and this outcome was unrelated to the treatment modality or WHO grade, compared with patients in whom 1p was intact (p < 0.05).
  • CONCLUSIONS: To the authors' knowledge, this study includes the largest published series of WHO Grade II oligodendroglioma and 1p analysis.
  • The results suggest that the association between long-term survival and 1p loss in oligodendroglioma is unrelated to treatment.
  • [MeSH-major] Chromosomes, Human, Pair 1. Genotype. Loss of Heterozygosity / genetics. Oligodendroglioma / genetics. Supratentorial Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Chromosomes, Human, Pair 19. Decision Support Techniques. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Reproducibility of Results. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619658.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res; 2006 Oct 15;66(20):9852-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.
  • Combined deletion of chromosomes 1p and 19q is associated with improved prognosis and responsiveness to therapy in patients with anaplastic oligodendroglioma.
  • Paraffin-embedded tissue was obtained from 21 Mayo Clinic patients and 98 patients enrolled in 2 North Central Cancer Treatment Group (NCCTG) low-grade glioma trials.
  • Upon culture, one oligodendroglioma contained an unbalanced 45,XX,t(1;19)(q10;p10).
  • Among Mayo Clinic oligodendrogliomas, the prevalence of fusion was 81%.
  • Among NCCTG patients, CEP1/19p12 fusion prevalence was 55%, 47%, and 0% among the oligodendrogliomas, mixed oligoastrocytomas, and astrocytomas, respectively.
  • The median OS for patients with low-grade oligodendroglioma was 9.1 years without fusion and 13.0 years with fusion (P = 0.01).
  • Like combined 1p/19q deletion, the 1;19 translocation is associated with superior OS and progression-free survival in low-grade glioma patients.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 12. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Cycle Proteins / genetics. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Female. Humans. Interphase. Male. Middle Aged. Multivariate Analysis. Prognosis. Translocation, Genetic

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17047046.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA114740; United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / P01 CA85799; United States / NCI NIH HHS / CA / P50 CA108961
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CNTRL protein, human; 0 / Cell Cycle Proteins
  •  go-up   go-down


36. Hata N, Shono T, Mizoguchi M, Matsumoto K, Guan Y, Nagata S, Hayashi K, Iwaki T, Sasaki T: Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy. Neurol Res; 2007 Oct;29(7):723-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy.
  • OBJECTIVE AND IMPORTANCE: Oligodendroglial tumors rarely occur after radiation therapy.
  • Here, we report a rare case of anaplastic oligodendroglioma arising after radiation therapy, in which genetic analysis was performed.
  • CLINICAL PRESENTATION AND INTERVENTION: A 41-year-old man who had received radiation therapy for a tumor of the suprasellar and pineal regions 31 years previously, presented with headache and progressive right hemiparesis.
  • Total removal of the tumor was performed through left frontoparietal craniotomy, and the histologic diagnosis was anaplastic oligodendroglioma.
  • Based on the genetic analysis, this tumor was considered to be sensitive to chemotherapy.
  • However, tumor recurrence was detected only 3 months after the surgery.
  • Despite additional radiochemotherapy, the tumor aggressively increased in size and the patient died with multiple recurrent tumors 1 year after surgery.
  • CONCLUSION: The anaplastic oligodendroglioma presented in this report showed a more aggressive clinical course than was expected from the genetic analysis.
  • The significance of 1p and 19q LOH in radiation-induced oligodendroglial tumors might differ from that in spontaneous counterparts.
  • [MeSH-major] Brain Neoplasms / genetics. Cell Transformation, Neoplastic / genetics. Frontal Lobe / pathology. Loss of Heterozygosity / genetics. Neoplasms, Radiation-Induced / genetics. Oligodendroglioma / genetics. Radiotherapy / adverse effects
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 19 / genetics. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Microsatellite Repeats / genetics. Neoplasm Recurrence, Local. Predictive Value of Tests. Treatment Failure


37. Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay JL, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith AM, Macdonald DR, Weaver S, Ramsay DA, Nimer SD, DeAngelis LM, Cairncross JG: High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro Oncol; 2006 Apr;8(2):183-8
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up.
  • We previously reported a phase 2 trial of 69 patients with newly diagnosed anaplastic or aggressive oligodendroglioma who were treated with intensive procarbazine, CCNU (lomustine), and vincristine (PCV) followed by high-dose thiotepa with autologous stem cell rescue.
  • Neither histology nor prior low-grade oligodendroglioma correlated with risk of relapse.
  • Persistent nonenhancing tumor at transplant was identified in our initial report as a significant risk factor for relapse; however, long-term follow-up has not confirmed this finding.
  • This treatment strategy affords long-term disease control to a subset of patients with newly diagnosed anaplastic oligodendroglioma without evidence of delayed neurotoxicity or myelodysplasia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Oligodendroglioma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Survival Analysis. Thiotepa / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Neurooncol. 2003 Nov;65(2):127-34 [14686732.001]
  • [Cites] Expert Opin Pharmacother. 2004 Feb;5(2):295-306 [14996626.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):77-81 [15072451.001]
  • [Cites] Arch Neurol. 1991 Feb;48(2):225-7 [1993014.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):1141-3 [10496285.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Neurology. 1996 Jan;46(1):203-7 [8559376.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):602-7 [8814163.001]
  • [Cites] J Clin Oncol. 1997 Dec;15(12):3427-32 [9396393.001]
  • [Cites] Med Pediatr Oncol. 1998 Jul;31(1):16-8 [9607424.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):567-73 [7928487.001]
  • (PMID = 16524945.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 905Z5W3GKH / Thiotepa
  • [Other-IDs] NLM/ PMC1871935
  •  go-up   go-down


38. Park CK, Kim JH, Moon MJ, Jung JH, Lim SY, Park SH, Kim JH, Kim DG, Jung HW, Cho BK, Paek SH: Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression. J Cancer Res Clin Oncol; 2008 Feb;134(2):255-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression.
  • PURPOSE: Frozen tumor tissues from a patient who showed rapid progression to anaplastic oligodendroglioma after near total resection of oligodendroglioma were used to examine differential expression of proteins to gain better understanding of the pathogenesis of malignant transformation.
  • RESULTS: Among 23 differentially expressed spots, overexpression of peroxiredoxin 6 and underexpression of rho GDP dissociation inhibitor alpha were confirmed to be valid after western blot and immunocytochemical analysis of oligodendroglioma tissue.
  • CONCLUSIONS: Abnormal expression of peroxiredoxin 6 and rho GDP dissociation inhibitor alpha may be associated with malignant transformation in oligodendroglioma and these proteins might be candidates of molecular predictive factors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic. Neoplasm Proteins / metabolism. Oligodendroglioma / metabolism
  • [MeSH-minor] Adult. Blotting, Western. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Disease Progression. Electrophoresis, Gel, Two-Dimensional. Guanine Nucleotide Dissociation Inhibitors / metabolism. Humans. Immunoenzyme Techniques. Male. Mass Spectrometry. Peroxiredoxin VI / metabolism. Proteomics. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. rho-Specific Guanine Nucleotide Dissociation Inhibitors

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Biol Toxicol. 2003 Oct;19(5):285-98 [14703116.001]
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):698-708 [15952716.001]
  • [Cites] FEBS Lett. 2004 Jul 2;569(1-3):1-6 [15225599.001]
  • [Cites] Histopathology. 1999 Apr;34(4):331-41 [10231401.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):532-5 [10952316.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6432-40 [14695145.001]
  • [Cites] J Neurosurg. 1992 Mar;76(3):428-34 [1738022.001]
  • [Cites] Cell. 1992 Aug 7;70(3):401-10 [1643658.001]
  • [Cites] Neurology. 2001 Oct 9;57(7):1278-81 [11591848.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Free Radic Biol Med. 2005 Jun 1;38(11):1422-32 [15890616.001]
  • [Cites] Int J Cancer. 2004 Sep 10;111(4):514-21 [15239128.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1018-34; discussion 1034-5 [7885546.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2496-501 [15059904.001]
  • [Cites] Int J Oncol. 2005 Apr;26(4):993-8 [15753994.001]
  • [Cites] Proteomics. 2005 May;5(7):1914-27 [15816005.001]
  • [Cites] Proteomics. 2005 Mar;5(4):1167-77 [15759318.001]
  • [Cites] Cancer. 2003 May 1;97(9):2254-61 [12712480.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1041-50 [10515227.001]
  • [Cites] J Pathol. 2002 Mar;196(3):316-23 [11857495.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jan;7(1):54-62 [16493413.001]
  • [Cites] Oncogene. 2000 Jun 15;19(26):3013-20 [10871853.001]
  • [Cites] Proteomics. 2006 Jun;6(11):3352-68 [16637015.001]
  • [Cites] J Neurosurg. 2002 Mar;96(3):559-64 [11892633.001]
  • [Cites] J Neurosci Res. 2002 Dec 15;70(6):794-8 [12444601.001]
  • [Cites] Int J Cancer. 1994 Apr 15;57(2):172-5 [8157354.001]
  • [Cites] J Cell Biol. 1997 Nov 17;139(4):1047-59 [9362522.001]
  • [Cites] Neurology. 2004 May 25;62(10 ):1783-7 [15159478.001]
  • [Cites] J Neurosurg. 2006 Apr;104(4):542-50 [16619658.001]
  • [Cites] Neurology. 2006 Mar 14;66(5):733-6 [16534112.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):544-58 [10850867.001]
  • [Cites] Oncogene. 2004 Sep 2;23 (40):6806-14 [15286718.001]
  • [Cites] Traffic. 2005 Nov;6(11):957-66 [16190977.001]
  • [Cites] Cell. 1995 Apr 7;81(1):53-62 [7536630.001]
  • (PMID = 17653765.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Guanine Nucleotide Dissociation Inhibitors; 0 / Neoplasm Proteins; 0 / rho-Specific Guanine Nucleotide Dissociation Inhibitors; EC 1.11.1.15 / PRDX6 protein, human; EC 1.11.1.15 / Peroxiredoxin VI
  •  go-up   go-down


39. Levidou G, Korkolopoulou P, Agrogiannis G, Paidakakos N, Bouramas D, Patsouris E: Low-grade oligodendroglioma of the pineal gland: a case report and review of the literature. Diagn Pathol; 2010;5:59
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade oligodendroglioma of the pineal gland: a case report and review of the literature.
  • BACKGROUND: Gliomas are a very rare subtype of pineal region tumours, whereas oligodendrogliomas of the pineal region are exceedingly rare, since there have been only 3 cases of anaplastic oligodedrogliomas reported this far.
  • METHODS-RESULTS: We present a case of a low-grade oligodendroglioma arising in the pineal gland of a 37 year-old woman.
  • Total resection was performed and histological examination showed that the cystic wall consisted of tumour cells with a central nucleus a perinuclear halo and minimal pleomorphism.
  • However, the diagnosis of a low grade oligodendroglioma of the pineal gland was assigned.
  • CONCLUSION: Although the spectrum of tumours arising in the pineal gland is broad, the reports of oligodendrogliomas confined to this location are exceedingly rare, and to the best of our knowledge there is no report of a low-grade oligodendroglioma.
  • [MeSH-major] Oligodendroglioma / pathology. Pinealoma / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Cell Proliferation. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1983 Jul;42(4):391-408 [6864234.001]
  • [Cites] J Morphol. 1982 Jul;173(1):73-86 [7108968.001]
  • [Cites] Surg Neurol. 1985 Feb;23(2):139-42 [3966205.001]
  • [Cites] Hum Pathol. 1995 Jan;26(1):20-30 [7821912.001]
  • [Cites] Surg Neurol. 1995 Jan;43(1):70-5; discussion 75-6 [7701429.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):53-8 [9548342.001]
  • [Cites] Brain Res. 1999 Sep 25;842(2):359-75 [10526132.001]
  • [Cites] Prog Brain Res. 1965;10:193-217 [14281603.001]
  • [Cites] Cancer. 2005 Apr 25;105(2):80-6 [15662708.001]
  • [Cites] Acta Neuropathol. 2005 Jul;110(1):27-38 [15920661.001]
  • [Cites] Pathol Res Pract. 2006;202(2):85-92 [16413691.001]
  • [Cites] Clin Neuropathol. 2006 Jan-Feb;25(1):18-24 [16465770.001]
  • [Cites] J Neurosurg. 2006 Sep;105(3):461-4 [16961143.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):307-14 [16645719.001]
  • [Cites] Minim Invasive Neurosurg. 2006 Aug;49(4):247-50 [17041839.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Clin Neuropathol. 2008 May-Jun;27(3):118-28 [18552083.001]
  • [Cites] J Pineal Res. 1984;1(4):323-37 [6545825.001]
  • [Cites] Brain Pathol. 2000 Jan;10(1):49-60 [10668895.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):239-49 [11767290.001]
  • [Cites] Neurol Med Chir (Tokyo). 2000 May;40(5):283-6 [11980097.001]
  • [Cites] Surg Neurol. 2002 Aug;58(2):111-7; discussion 117 [12453646.001]
  • [Cites] Curr Neurol Neurosci Rep. 2003 May;3(3):223-8 [12691627.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):645-52 [15497117.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):99-103 [7006792.001]
  • [Cites] Pediatrics. 1984 Jul;74(1):97-102 [6739222.001]
  • (PMID = 20849631.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2949720
  •  go-up   go-down


40. Jäger HR, Waldman AD, Benton C, Fox N, Rees J: Differential chemosensitivity of tumor components in a malignant oligodendroglioma: assessment with diffusion-weighted, perfusion-weighted, and serial volumetric MR imaging. AJNR Am J Neuroradiol; 2005 Feb;26(2):274-8
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential chemosensitivity of tumor components in a malignant oligodendroglioma: assessment with diffusion-weighted, perfusion-weighted, and serial volumetric MR imaging.
  • We report the case of malignant oligodendroglioma in a 36-year-old man who underwent diffusion-weighted, perfusion-weighted, and volumetric MR imaging before and after PCV (procarbazine, CCNU, vincristine) chemotherapy.
  • The tumor regions exhibiting a low apparent diffusion coefficient and increased relative cerebral blood volume showed a marked response to chemotherapy and dramatic decrease in volume, whereas the remaining tumor regions showed little change.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging. Oligodendroglioma / drug therapy. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging / methods. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709124.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G116/143
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Makuria AT, Henderson FC, Rushing EJ, Hartmann DP, Azumi N, Ozdemirli M: Oligodendroglioma with neurocytic differentiation versus atypical extraventricular neurocytoma: a case report of unusual pathologic findings of a spinal cord tumor. J Neurooncol; 2007 Apr;82(2):199-205
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendroglioma with neurocytic differentiation versus atypical extraventricular neurocytoma: a case report of unusual pathologic findings of a spinal cord tumor.
  • Differentiating oligodendroglioma from extraventricular neurocytoma by conventional light microscopy alone can present a diagnostic challenge.
  • We report pathologic findings of an unusual spinal cord tumor from a 33-year-old male patient which showed hybrid features of oligodendroglioma and extraventricular neurocytoma.
  • Histologic examination revealed a clear cell neoplasm containing ganglion-like cells and calcifications, prompting the differential diagnosis of oligodendroglioma and extraventricular neurocytoma.
  • Molecular studies with fluorescent in situ hybridization (FISH) revealed chromosome 1p/(partial) 19q deletions, a finding commonly observed in oligodendroglioma.
  • The proliferation index (using antibody MIB1) of the tumor was approximately 30%.
  • Because there are differences in patient management and long-term prognosis, it is important to attempt to distinguish between oligodendroglioma and neurocytoma.
  • This unusual case and similar rare reported cases support the need to reclassify tumors showing pathologic features common to both neurocytoma and oligodendroglioma as a unique entity, while the effort continues to identify the cell of origin.
  • [MeSH-major] Neurocytoma / pathology. Oligodendroglioma / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Differentiation. Humans. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17039400.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


42. Omalu BI, Nnebe-Agumadu UH: Occurrence of anaplastic oligodendroglioma in a patient with Williams syndrome: a case report with analysis of mutational profile of tumor. Niger J Clin Pract; 2009 Jun;12(2):200-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of anaplastic oligodendroglioma in a patient with Williams syndrome: a case report with analysis of mutational profile of tumor.
  • Chromosome 7q contains putative tumor suppressor genes and is one of the chromosomes that are frequently involved in chromosomal aberrations in human malignancies.
  • We report a case of anaplastic oligodendroglioma that occurred in a 31-year-old man with Williams syndrome.
  • We draw attention to this apparently rare or possibly under-reported occurrence of tumors in patients with Williams syndrome and suggest that Central Nervous System [CNS] tumors be considered as differential diagnoses in such patients when they present with unanticipated neurologic symptoms that are not attributable to those commonly associated with Williams syndrome.
  • [MeSH-major] Brain Neoplasms / epidemiology. Oligodendroglioma / epidemiology. Parietal Lobe. Williams Syndrome / epidemiology
  • [MeSH-minor] Adult. Comorbidity. DNA Mutational Analysis. Humans. Loss of Heterozygosity. Male. Neurologic Examination


43. Sega S, Horvat A, Popovic M: Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-beta treated multiple sclerosis patients. Report of two cases. Clin Neurol Neurosurg; 2006 Mar;108(3):259-65
Hazardous Substances Data Bank. Interferon Beta-1b .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligodendroglioma and gliomatosis type 2 in interferon-beta treated multiple sclerosis patients. Report of two cases.
  • The concurrence of multiple sclerosis (MS) and brain tumors has been reported, but it is not known whether MS patients are at greater risk of harbouring the latter.
  • The most common cerebral neoplasms reported in MS patients were oligodendroglioma, astrocytoma, glioblastoma and gliomatosis.
  • MS can also present as a mass lesion that mimics a brain tumor.
  • Two cases of coincidental MS and brain tumors are reviewed.
  • One is a 26-year-old woman with relapsing-remitting MS and an anaplastic oligodendroglioma, the other a 49-year-old woman patient with relapsing-remitting MS and gliomatosis type 2.
  • Both patients were treated with interferon-beta1b and both died from the tumor.
  • The concurrence of MS and brain tumors could be purely coincidental, or the result of neoplastic transformation of reactive glial cells in the areas of demyelination.
  • The combination of a brain tumor and MS, and interferon-beta treatment could also be pure coincidence or an unknown side effect of treatment.
  • Although interferon-beta has been said to function as a tumor-suppressor protein, the influence of long-term treatment of MS patients on cancer development is not known.
  • [MeSH-major] Brain Neoplasms / complications. Glioblastoma / complications. Multiple Sclerosis, Relapsing-Remitting / complications. Oligodendroglioma / complications
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Adult. Fatal Outcome. Female. Humans. Interferon beta-1b. Interferon-beta / therapeutic use. Middle Aged


44. Panesar NK, Sidhu JS: Uterine cervical teratoma with divergent neuroepithelial differentiation and development of an oligodendroglioma: report of a case and review of the literature. Ann Diagn Pathol; 2007 Aug;11(4):293-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine cervical teratoma with divergent neuroepithelial differentiation and development of an oligodendroglioma: report of a case and review of the literature.
  • A uterine cervical teratoma with divergent neuroepithelial differentiation and/or development of a neurological tumor has never been reported.
  • We describe a case of uterine cervical teratoma exhibiting ectodermal, endodermal, mesodermal, and various types of neuroepithelial differentiation and development of a small oligodendroglioma in a 38-year-old female.
  • The presence of immature neuroepithelium defines this teratoma as immature, and the development of a low-grade malignant neoplasm from one of its components makes it malignant.
  • [MeSH-major] Neoplasms, Multiple Primary / pathology. Oligodendroglioma / pathology. Teratoma / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17630116.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol; 2006 Jun 20;24(18):2707-14
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
  • PURPOSE: Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are treated with surgery and radiotherapy (RT) at diagnosis, but they also respond to procarbazine, lomustine, and vincristine (PCV), raising the possibility that early chemotherapy will improve survival.
  • Progression-free survival time favored PCV plus RT (2.6 years v 1.7 years for RT alone; HR = 0.69; 95% CI, 0.52 to 0.91; P = .004), but 65% of patients experienced grade 3 or 4 toxicity, and one patient died.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Oligodendroglioma / drug therapy. Oligodendroglioma / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Dose Fractionation. Female. Humans. Lomustine / therapeutic use. Loss of Heterozygosity. Male. Middle Aged. Procarbazine / therapeutic use. Proportional Hazards Models. Radiotherapy, High-Energy. Survival Analysis. Vincristine / therapeutic use


46. Brown R, Zlatescu M, Sijben A, Roldan G, Easaw J, Forsyth P, Parney I, Sevick R, Yan E, Demetrick D, Schiff D, Cairncross G, Mitchell R: The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res; 2008 Apr 15;14(8):2357-62
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma.
  • BACKGROUND: Some patients with low-grade glioma have extraordinarily long survival times; current, early treatment does not prolong their lives.
  • METHODS: In a study of oligodendrogliomas, we used a quantitative method of MR analysis based on the S-transform to investigate whether codeletion of chromosomes 1p and 19q, a marker of good prognosis, could be predicted accurately by measuring image texture.
  • CONCLUSIONS: This new method of MR image interpretation may have the potential to augment the diagnostic assessment of patients with suspected low-grade glioma.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Magnetic Resonance Imaging / methods. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Female. Humans. Male

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18413825.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Hägerstrand D, Smits A, Eriksson A, Sigurdardottir S, Olofsson T, Hartman M, Nistér M, Kalimo H, Ostman A: Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker. Neuro Oncol; 2008 Feb;10(1):2-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker.
  • Grade II gliomas are morphologically and clinically heterogeneous tumors for which histopathological typing remains the major tool for clinical classification.
  • To what extent the major histological subtypes - astrocytomas, oligodendrogliomas, and oligoastrocytomas - constitute true biological entities is largely unresolved.
  • In this study, 23 grade II gliomas were expression-profiled and subjected to hierarchical clustering.
  • All six oligodendrogliomas were grouped together in one of two major clusters; a significant correlation was thus observed between gene expression and histopathological subtype.
  • Supervised analyses were performed to identify genes differentiating oligodendrogliomas from other grade II tumors.
  • The expression of the rPTP beta/zeta protein in oligodendrogliomas and astrocytomas was further validated by immunohistochemistry in an independent set of tumors.
  • All 11 oligodendrogliomas of this set displayed strong staining.
  • In summary, this study demonstrates a correlation between gene expression pattern and histological subtype in grade II gliomas.
  • Furthermore, the results from the immunohistochemical analyses of rPTPbeta/zeta expression should prompt further evaluation of this protein as a novel oligodendroglioma marker.

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):635-40 [11148662.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):411-4 [12355066.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1462-9 [12424117.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Oncogene. 2003 Jul 31;22(31):4918-23 [12894235.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6661-8 [14555979.001]
  • [Cites] Expert Opin Ther Targets. 2004 Jun;8(3):211-20 [15161428.001]
  • [Cites] Neurochem Res. 2004 Jun;29(6):1213-22 [15176478.001]
  • [Cites] Bioinformatics. 2004 Jul 22;20(11):1797-8 [14988123.001]
  • [Cites] Oncogene. 2004 Aug 5;23(35):6012-22 [15208679.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1294-301 [9193320.001]
  • [Cites] Curr Opin Neurobiol. 1998 Feb;8(1):117-27 [9568399.001]
  • [Cites] Lab Invest. 1998 May;78(5):643-4 [9605190.001]
  • [Cites] J Cell Biol. 1998 Jul 13;142(1):203-16 [9660874.001]
  • [Cites] Bioessays. 1998 Jun;20(6):463-72 [9699458.001]
  • [Cites] Brain Res Mol Brain Res. 1998 Sep 18;60(1):77-88 [9748513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2907-12 [10077610.001]
  • [Cites] J Neurooncol. 1999 May;42(3):259-69 [10433109.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4051-8 [15899794.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):159-67 [16397228.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2271-8 [16489031.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):735-45 [11702861.001]
  • (PMID = 18003890.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 5
  • [Other-IDs] NLM/ PMC2600835
  •  go-up   go-down


48. Blesa D, Mollejo M, Ruano Y, de Lope AR, Fiaño C, Ribalta T, García JF, Campos-Martín Y, Hernández-Moneo JL, Cigudosa JC, Meléndez B: Novel genomic alterations and mechanisms associated with tumor progression in oligodendroglioma and mixed oligoastrocytoma. J Neuropathol Exp Neurol; 2009 Mar;68(3):274-85
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel genomic alterations and mechanisms associated with tumor progression in oligodendroglioma and mixed oligoastrocytoma.
  • Combined 1p/19q deletions are very prevalent in oligodendrogliomas (OGs) and, to a lesser extent, in oligoastrocytomas (OAs).
  • This genome duplication was frequent in high-grade OGs and was strongly correlated with Ki-67 expression; thus, it could be related to tumor progression.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Comparative Genomic Hybridization. Female. Gene Dosage. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Loss of Heterozygosity. Male. Middle Aged

  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19225409.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermani M, GICNO: Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol; 2006 Oct 10;24(29):4746-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
  • PURPOSE: To date, no data are available on the relationship between 1p/19q deletions and the response to temozolomide (TMZ) in primary anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) recurrent after surgery and standard radiotherapy.
  • CONCLUSION: TMZ is active in anaplastic oligodendroglial tumors treated at first recurrence.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Dacarbazine / analogs & derivatives. O(6)-Methylguanine-DNA Methyltransferase / genetics. Oligodendroglioma / drug therapy. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosome Deletion. DNA Methylation. DNA Repair. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Promoter Regions, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954518.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


50. Tang BN, Sadeghi N, Branle F, De Witte O, Wikler D, Goldman S: Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol; 2005 Jan;71(2):161-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma.
  • 11C-Methionine (MET) is a useful positron emission tomography (PET) tracer for the evaluation of low-grade gliomas.
  • Among these tumors, a high percentage of low-grade oligodendrogliomas (ODG) are sensitive to chemotherapy with procarbazine, CCNU, and vincristine (PCV). We aimed at:.
  • AVI was calculated as the sum over all ROI of tumor volumex(tumor mean count/cerebellum count).
  • Tumor volume measurements on MRI, were based on signal abnormalities visually detected on fluid-attenuated inversion recovery (FLAIR) sequences.
  • Likewise, we observed a decrease in tumor volume estimated from the FLAIR signal (31.37+/-11.99 post-PCV vs. 67.95+/-39.96 prior PCV, P=0.03) although AVI decrease after PCV was significantly more pronounced (P=0.015).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Lomustine / therapeutic use. Magnetic Resonance Imaging. Methionine / pharmacokinetics. Oligodendroglioma / drug therapy. Positron-Emission Tomography. Procarbazine / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. (L)-Methionine .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690133.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; AE28F7PNPL / Methionine; PCV protocol
  •  go-up   go-down


51. Tews B, Felsberg J, Hartmann C, Kunitz A, Hahn M, Toedt G, Neben K, Hummerich L, von Deimling A, Reifenberger G, Lichter P: Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int J Cancer; 2006 Aug 15;119(4):792-800
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling.
  • Loss of heterozygosity (LOH) on chromosomal arms 1p and 19q is the most common genetic alteration in oligodendroglial tumors and associated with response to radio- and chemotherapy as well as favorable prognosis.
  • Using microsatellite analysis, we previously identified the chromosomal regions 1p36.22-p36.31 and 19q13.3, as candidate tumor suppressor gene regions being commonly deleted in these tumors.
  • To identify genes within these regions that are downregulated in oligodendroglial tumors with LOH 1p/19q, we performed cDNA microarray-based RNA expression profiling of 35 gliomas with known allelic status on 1p and 19q, including 7 oligodendrogliomas and 8 diffuse astrocytomas of World Health Organization (WHO) grade II, as well as 14 anaplastic oligodendrogliomas and 6 anaplastic oligoastrocytomas of WHO grade III.
  • In addition, we found that the cytosolic phospholipase A2 (PLA2G4C) gene at 19q13.3 demonstrated significantly lower expression in anaplastic oligodendrogliomas (WHO grade III) when compared to well-differentiated oligodendrogliomas (WHO grade II).
  • Taken together, our study provides a set of interesting novel candidate genes that may play important roles in the pathogenesis of oligodendroglial tumors.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Oligodendroglioma / genetics. Oligonucleotide Array Sequence Analysis. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. DNA, Complementary / genetics. Down-Regulation. Female. Humans. Male. Middle Aged. Transcription, Genetic / genetics. Up-Regulation

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16550607.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


52. Kapoor GS, Gocke TA, Chawla S, Whitmore RG, Nabavizadeh A, Krejza J, Lopinto J, Plaum J, Maloney-Wilensky E, Poptani H, Melhem ER, Judy KD, O'Rourke DM: Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol; 2009 May;92(3):373-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status.
  • 1p19q LOH has been shown to predict radio- and chemosensitivity and prolonged survival in oligodendrogliomas (OLs).
  • We have recently shown that magnetic resonance perfusion-weighted imaging (MR-PWI) may be useful in predicting the histopathological grade or cytogenetic type of oligodendroglial neoplasms.
  • MR-PWI allows noninvasive determination of relative tumor blood volume (rTBV), which may reflect the degree of neoplastic angiogenesis and metabolism.
  • The present study was aimed to correlate rTBV to the angiogenic markers and EGFR expression in oligodendroglial tumors with 1p/19q LOH or 1p LOH (Group 1) and 1p19q intact alleles or 19q LOH (Group 2), respectively.
  • In WHO grade II neoplasms, Group 1 showed significantly greater rTBV than Group 2 (P = 0.013).
  • However, the differences between Group 1 and Group 2 were not significant in grade III tumors.
  • Probe-based real-time RT-PCR analyses showed that 12% of Group 2 high-grade tumors with intact 1p19q exhibited dramatic EGFR overexpression (designated EGFR-high).
  • Grade III neoplasms showed a significantly higher rTBV than grade II neoplasms.
  • Therefore, the combined use of extensive molecular profiling and advanced MR imaging modalities may improve the accuracy of tumor grading, provide prognostic information, and has the potential to influence treatment decisions.
  • [MeSH-major] Brain Neoplasms / diagnosis. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Neovascularization, Pathologic / diagnosis. Oligodendroglioma / diagnosis. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Humans. In Situ Hybridization, Fluorescence. Loss of Heterozygosity. Magnetic Resonance Angiography. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19357963.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA-90586
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


53. Wharton SB, Maltby E, Jellinek DA, Levy D, Atkey N, Hibberd S, Crimmins D, Stoeber K, Williams GH: Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells. Acta Neuropathol; 2007 Feb;113(2):119-27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells.
  • Oligodendrogliomas may be divided into those with deletion of chromosomes 1p and 19q (Del+), and those without (Del-).
  • Fluorescence in situ hybridisation with probes to 1p and 19q was used to determine the deletion status of 54 oligodendrogliomas, including WHO grades II and III.
  • Del+ oligodendrogliomas showed a higher apoptotic index than Del- tumours (P=0.037); this was not accounted for by differences in tumour grade or in proliferation.
  • There were no differences in the Mcm2-Ki67 index or in the geminin/Ki67 ratio between the subgroups, but grade III tumours showed a higher proportion of licensed non-proliferating cells than grade II tumours (P=0.001).
  • An increased susceptibility to apoptosis in oligodendrogliomas with 1p+/-19q deletion may be important in their improved clinical outcome compared to Del- tumours.
  • [MeSH-major] Apoptosis / physiology. Cell Proliferation. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Cell Survival. Cytogenetics / methods. DNA Replication. Female. Humans. In Situ Hybridization, Fluorescence / methods. Ki-67 Antigen / metabolism. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):379-85 [15455350.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):245-54 [15674481.001]
  • [Cites] J Pathol. 2005 Feb;205(3):318-28 [15682442.001]
  • [Cites] Histopathology. 2005 Mar;46(3):307-13 [15720416.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2510-7 [15814627.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2827-43 [15838518.001]
  • [Cites] J Clin Pathol. 2005 Jul;58(7):710-4 [15976337.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Acta Neuropathol. 2005 Jul;110(1):27-38 [15920661.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Oct;31(5):455-66 [16150117.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):939-45 [16189522.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1295-300 [16278669.001]
  • [Cites] Cell Death Differ. 2006 Jan;13(1):5-11 [16123777.001]
  • [Cites] J Neurosurg. 2006 Apr;104(4):542-50 [16619658.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 7:vii115-23 [16760273.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Lancet. 1999 Oct 30;354(9189):1524-5 [10551502.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1253-62 [11290543.001]
  • [Cites] Nat Cell Biol. 2001 Feb;3(2):107-13 [11175741.001]
  • [Cites] Science. 2000 Dec 22;290(5500):2309-12 [11125146.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 11):2027-41 [11493639.001]
  • [Cites] Neuropathol Appl Neurobiol. 2001 Aug;27(4):305-13 [11532161.001]
  • [Cites] J Pathol. 2001 Nov;195(4):457-62 [11745678.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jan;61(1):58-63 [11829344.001]
  • [Cites] Acta Neuropathol. 2002 Mar;103(3):267-75 [11907807.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:a1-9 [12456321.001]
  • [Cites] J Pathol. 2003 Feb;199(2):221-8 [12533835.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):262-9 [15199392.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):714-9 [15266314.001]
  • [Cites] Ann Neurol. 1988 Apr;23(4):360-4 [3382171.001]
  • [Cites] Arch Neurol. 1991 Feb;48(2):225-7 [1993014.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Hepatology. 1995 May;21(5):1465-8 [7737654.001]
  • [Cites] Neurosci Lett. 1995 Aug 4;195(2):81-4 [7478273.001]
  • [Cites] Neuropathol Appl Neurobiol. 1995 Aug;21(4):352-61 [7494604.001]
  • [Cites] Neurochem Int. 1997 Aug;31(2):245-50 [9220457.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Feb;24(1):21-8 [9549725.001]
  • [Cites] Cell. 1998 Jun 12;93(6):1043-53 [9635433.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14932-7 [9843993.001]
  • [Cites] Br J Neurosurg. 1998 Dec;12(6):539-46 [10070463.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] J Cell Sci. 2004 Nov 15;117(Pt 24):5875-86 [15522891.001]
  • (PMID = 17160531.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  • [Other-IDs] NLM/ PMC1781098
  •  go-up   go-down


54. Miwa T, Hirose Y, Sasaki H, Ikeda E, Yoshida K, Kawase T: Genetic characterization of adult infratentorial gliomas. J Neurooncol; 2009 Feb;91(3):251-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic characterization of adult infratentorial gliomas.
  • Adult infratentorial gliomas are rare and have not been well studied.
  • Nineteen adult infratentorial gliomas were analyzed for chromosomal aberration by comparative genomic hybridization, and for expression of p53 and epidermal growth factor receptor (EGFR) by immunohistochemistry.
  • However, the gain of 7q, the characteristic abnormality of supratentorial astrocytomas commonly associated with the gaining of 7p, was observed only in 1 of 11 adult infratentorial astrocytic tumors.
  • Combined losses of 1p and 19q, the genetic hallmark of oligodendroglioma, were not observed.
  • Our findings might suggest the presence of distinct tumorigenic pathway in adult infratentorial gliomas.
  • [MeSH-major] Brain Neoplasms / genetics. Frontal Lobe / pathology. Glioma / genetics. Receptor, Epidermal Growth Factor / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Chromosome Aberrations. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Chromosomes, Human, Pair 7 / genetics. Comparative Genomic Hybridization. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941867.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


55. Houben MP, Aben KK, Teepen JL, Schouten-Van Meeteren AY, Tijssen CC, Van Duijn CM, Coebergh JW: Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003. Acta Oncol; 2006;45(3):272-9
Genetic Alliance. consumer health - Glioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
  • We therefore investigated trends in the incidence of childhood and adult glioma in The Netherlands from 1989 to 2003.
  • In adult astrocytic glioma, a significantly increasing incidence of high-grade astrocytoma was balanced by simultaneous decreases of low-grade astrocytoma, astrocytoma with unknown malignancy grade and glioma of uncertain histology.
  • Stable incidence rates of adult and childhood glioma suggest that no major changes in environmental risk factors have occurred, which influenced the incidence of glioma in the studied period.
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / epidemiology. Child. Child, Preschool. Cohort Studies. Ependymoma / epidemiology. Europe / epidemiology. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Netherlands / epidemiology. Oligodendroglioma / epidemiology. Sex Characteristics. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644569.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


56. Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG, Abrey LE: A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol; 2008 Sep;89(2):187-93
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.
  • BACKGROUND: Anaplastic oligodendrogliomas (AO) and anaplastic oligoastrocytomas (AOA) are currently treated with a combination of surgery, radiotherapy and chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / therapy. Brain Neoplasms / therapy. Oligodendroglioma / therapy. Radiotherapy, Adjuvant / methods
  • [MeSH-minor] Adult. Busulfan / administration & dosage. Combined Modality Therapy / methods. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Retrospective Studies. Survival Analysis. Thiotepa / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458821.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 905Z5W3GKH / Thiotepa; G1LN9045DK / Busulfan
  •  go-up   go-down


57. Kreiger PA, Okada Y, Simon S, Rorke LB, Louis DN, Golden JA: Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol; 2005 Apr;109(4):387-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas.
  • Pediatric oligodendrogliomas are rare neoplasms and have not been characterized extensively either pathologically or genetically.
  • Given the recent interest in the significance of chromosomal losses in predicting the clinical course and in establishing uniform diagnoses of adult oligodendrogliomas, we reviewed the pathological and clinical features of a series of pediatric oligodendrogliomas and determined their 1p and 19q status using fluorescence in situ hybridization.
  • Of 19 tumors originally diagnosed as oligodendroglioma, 7 were oligodendroglioma, 3 were anaplastic oligodendroglioma, 3 were oligoastrocytoma, and 6 were reclassified.
  • Only one tumor, an anaplastic oligodendroglioma, had 1p loss; none had 19q loss.
  • The single patient whose tumor had 1p loss did not have a particularly favorable clinical course.
  • These results suggest that pediatric oligodendrogliomas arise by molecular alterations distinct from adult oligodendrogliomas, and such molecular alterations do not hold immediate promise as an adjunct to the diagnosis of pediatric oligodendrogliomas.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Oligodendroglioma / genetics
  • [MeSH-minor] Actins / metabolism. Adolescent. Adult. Antigens, CD20 / metabolism. Antigens, CD45 / metabolism. Cell Count / methods. Child. Child, Preschool. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry / methods. In Situ Hybridization / methods. Infant, Newborn. Ki-67 Antigen / metabolism. Male. Neurofilament Proteins / metabolism. Synaptophysin / metabolism. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739101.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA57683
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD20; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Neurofilament Proteins; 0 / Synaptophysin; 0 / Vimentin; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


58. Maire JP, Huchet A, Catry-Thomas I: [Radiotherapy of adult glial tumors: new developments and perspectives]. Rev Neurol (Paris); 2008 Jun-Jul;164(6-7):531-41
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiotherapy of adult glial tumors: new developments and perspectives].
  • [Transliterated title] Radiothérapie des tumeurs gliales de l'adulte : actualités et perspectives.
  • Adult gliomas (WHO grade II, III and IV) are heterogeneous primitive brain tumors.
  • Median survivals are different with regard to the tumor grade.
  • However, genetic and biological factors also are important prognostic factors such as inactivation of the MGMT gene for glioblastomas and loss of heterozygosity (LOH) 1p/19q, usually associated with pure oligodendroglioma.
  • During the 1990s, temozolomide (TMZ) was specifically developed as a chemotherapy agent against primary brain tumors.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Radiotherapy / trends
  • [MeSH-minor] Adult. Astrocytoma / radiotherapy. Glioblastoma / radiotherapy. Humans. Medical Oncology / trends. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565351.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 89
  •  go-up   go-down


59. Bauer R, Dobesberger J, Unterhofer C, Unterberger I, Walser G, Bauer G, Trinka E, Ortler M: Outcome of adult patients with temporal lobe tumours and medically refractory focal epilepsy. Acta Neurochir (Wien); 2007 Dec;149(12):1211-6; discussion 1216-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of adult patients with temporal lobe tumours and medically refractory focal epilepsy.
  • Among these, 14 adult patients exhibited temporal lobe neoplasms associated with TLE.
  • One patient with an astrocytoma grade III underwent a second and third operation for recurrent disease.
  • Histological results: Astrocytoma 5 patients, ganglioglioma/gangliocytoma 5, oligodendroglioma 2, ependymoma 1 and dysembryoplastic neuroepithelial tumour (DNET) 1.
  • [MeSH-major] Brain Neoplasms / surgery. Epilepsy, Temporal Lobe / surgery. Postoperative Complications / etiology. Temporal Lobe / surgery
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / surgery. Electroencephalography. Ependymoma / surgery. Female. Follow-Up Studies. Ganglioglioma. Ganglioneuroma. Hemianopsia / etiology. Humans. Male. Middle Aged. Neuroectodermal Tumors, Primitive / surgery. Neurologic Examination. Oligodendroglioma / surgery. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940725.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


60. Taphoorn MJ, van den Bent MJ, Mauer ME, Coens C, Delattre JY, Brandes AA, Sillevis Smitt PA, Bernsen HJ, Frénay M, Tijssen CC, Lacombe D, Allgeier A, Bottomley A, European Organisation for Research and Treatment of Cancer: Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol; 2007 Dec 20;25(36):5723-30
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.
  • PURPOSE: Little is known about the health-related quality of life (HRQOL) of patients treated for anaplastic oligodendrogliomas.
  • PATIENTS AND METHODS: Adult patients with anaplastic oligodendrogliomas received RT alone or RT plus PCV chemotherapy.
  • HRQOL was assessed with the EORTC Quality of Life Questionnaire C30 and Brain Cancer Module.
  • [MeSH-major] Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy. Quality of Life

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Apr 20;26(12):2061-2; author reply 2062 [18421064.001]
  • (PMID = 18089866.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10CA11488-30; United States / NCI NIH HHS / CA / 5U10CA11488-31; United States / NCI NIH HHS / CA / 5U10CA11488-32; United States / NCI NIH HHS / CA / 5U10CA11488-33; United States / NCI NIH HHS / CA / 5U10CA11488-34
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


61. Devaux B, Turak B, Roujeau T, Page P, Cioloca C, Ricci AC, Bret P, Nataf F, Roux FX: [Adult supratentorial oligodendrogliomas. Surgical treatment: indications and techniques]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):353-67

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult supratentorial oligodendrogliomas. Surgical treatment: indications and techniques].
  • [Transliterated title] Oligodendrogliomes supratentoriels de l'adulte. Traitement chirurgical: indications et techniques.
  • Surgical resection is the first step in the treatment of adult supratentorial oligodendrogliomas (OLG).
  • Surgical or stereotactic biopsy is the first surgical procedure which enables confirmation of the diagnosis suggested on imaging, assessment of extension of tumor cell infiltration beyond abnormalities limit described an imaging, and currently available molecular biology studies.
  • Biopsies may be the only surgical procedure in patients having a deep-seated tumor with minimal mass effect, or prior to a surgical resection or a "wait and watch" strategy.
  • A wait and watch strategy is therefore warranted in patients with a tumor aspect suggestive of a grade A OLG; surgical resection may be indicated later.
  • There is a current trend for maximal safe resection, preserving functional cerebral areas, since truly complete resection of the tumor including infiltration is exceptional.
  • [MeSH-major] Neurosurgical Procedures / methods. Oligodendroglioma / surgery. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292178.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


62. Bauman G, Fisher B, Watling C, Cairncross JG, Macdonald D: Adult supratentorial low-grade glioma: long-term experience at a single institution. Int J Radiat Oncol Biol Phys; 2009 Dec 1;75(5):1401-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult supratentorial low-grade glioma: long-term experience at a single institution.
  • PURPOSE: To report the long-term follow-up of a cohort of adult patients with supratentorial low-grade glioma treated at a single institution.
  • METHODS AND MATERIALS: A cohort of 145 adult patients treated at the London Regional Cancer Program between 1979 and 1995 was reviewed.
  • Function among long-term survivors without tumor progression was good to excellent for most patients.
  • CONCLUSION: Low-grade glioma is a chronic disease, with most patients dying of their disease.
  • [MeSH-major] Astrocytoma / radiotherapy. Oligodendroglioma / radiotherapy. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Age Factors. Disease-Free Survival. Female. Follow-Up Studies. Headache / etiology. Humans. Karnofsky Performance Status. Male. Middle Aged. Quality of Life. Regression Analysis. Salvage Therapy / methods. Seizures / etiology. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19395201.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quiñones-Hinojosa A: Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg; 2010 Jan;112(1):10-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas.
  • OBJECT: Unlike their malignant counterparts, low-grade gliomas are associated with prolonged survival.
  • The authors set out to determine factors that were independently associated with recurrence and malignant degeneration in patients who underwent resection of a hemispheric low-grade glioma.
  • METHODS: Adult patients who underwent craniotomy and resection of a hemispheric low-grade glioma (WHO Grade II) at the Johns Hopkins Medical Institution's academic tertiary-care institution between 1996 and 2006 were retrospectively reviewed.
  • Multivariate proportional hazards regression analyses were used to identify associations with tumor recurrence and malignant degeneration.
  • RESULTS: Of the 191 consecutive patients with low-grade gliomas in this series (89 fibrillary astrocytomas, 89 oligodendrogliomas, and 13 mixed gliomas), 83 (43%) and 44 (23%) experienced tumor recurrence and malignant degeneration at last follow-up, respectively.
  • Independent predictors of recurrence were duration of longest lasting symptom (relative risk [RR] 0.978, 95% CI 0.954-0.996, p = 0.01), tumor size (RR 1.328, 95% CI 1.109-1.602, p = 0.002), and preoperative contrast enhancement (RR 2.558, 95% CI 1.241-5.021, p = 0.01).
  • Independent factors associated with malignant degeneration were fibrillary astrocytoma pathology (RR 1.800, 95% CI 1.008-4.928, p = 0.04), tumor size (RR 1.086, 95% CI 1.044-1.358, p = 0.04), and gross-total resection (RR 0.526, 95% CI 0.221-1.007, p = 0.05).
  • CONCLUSIONS: The identification and consideration of factors associated with recurrence and malignant progression may help guide treatment strategies aimed at delaying recurrence and preventing malignant degeneration for patients with hemispheric low-grade gliomas.
  • [MeSH-major] Brain Neoplasms / surgery. Glioma / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Astrocytoma / pathology. Astrocytoma / surgery. Disease Progression. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Multivariate Analysis. Neoplasm Staging. Oligodendroglioma / pathology. Oligodendroglioma / surgery. Proportional Hazards Models. Retrospective Studies. Risk Factors. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361270.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Boman KK, Hovén E, Anclair M, Lannering B, Gustafsson G: Health and persistent functional late effects in adult survivors of childhood CNS tumours: a population-based cohort study. Eur J Cancer; 2009 Sep;45(14):2552-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health and persistent functional late effects in adult survivors of childhood CNS tumours: a population-based cohort study.
  • Survivors of central nervous system (CNS) tumours are particularly vulnerable to tumour- and treatment-related disability.
  • We present the incidence of specific and overall functional and health-related late effects in a national adult survivor cohort.
  • Oligodendroglioma, mixed/unspecified glioma, intracranial germ cell tumour and medulloblastoma survivors had poorest overall health.
  • Least late effects were found for other specified/unspecified CNS tumours (including meningeoma and nerve sheath tumours), and for astrocytoma.
  • Comparisons with controls confirm persistent disability in multiple functional domains in adult CNS tumour survivors.
  • [MeSH-major] Central Nervous System Neoplasms / complications. Health Status. Survivors
  • [MeSH-minor] Activities of Daily Living. Adolescent. Adult. Age Factors. Case-Control Studies. Child. Child, Preschool. Cognition Disorders / epidemiology. Cohort Studies. Female. Humans. Incidence. Male. Pain / epidemiology. Quality of Life. Risk Factors. Self Care. Sensation Disorders / epidemiology. Sweden / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19616428.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


65. Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DT, Collins VP: IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol; 2009 Aug;11(4):341-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
  • Codon 132 mutation was seen in 54% of astrocytomas and 65% of oligodendroglial tumors but in only 6% of glioblastomas (3% of primary and 50% of secondary glioblastomas).
  • There were no mutations in any other type of tumor studied.
  • While mutations in the tumor protein p53 gene (TP53) and total 1p/19q deletions were mutually exclusive, IDH1 mutations were strongly correlated with these genetic abnormalities.
  • The data indicate that IDH1 mutation combined with either TP53 mutation or total 1p/19q loss is a frequent and early change in the majority of oligodendroglial tumors, diffuse astrocytomas, anaplastic astrocytomas, and secondary glioblastomas but not in primary glioblastomas.
  • [MeSH-major] Brain Neoplasms / genetics. Glioblastoma / genetics. Isocitrate Dehydrogenase / genetics. Mutation / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Biomarkers, Tumor / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Comparative Genomic Hybridization. Exons / genetics. Genotype. Humans. Loss of Heterozygosity. Prognosis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 1999 Nov;58(11):1170-83 [10560660.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30527-33 [10521434.001]
  • [Cites] Cell Growth Differ. 2000 Jul;11(7):373-84 [10939591.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Feb;34(2):148-57 [11809417.001]
  • [Cites] Free Radic Biol Med. 2002 Jun 1;32(11):1185-96 [12031902.001]
  • [Cites] Free Radic Res. 2003 Mar;37(3):309-16 [12688426.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33946-57 [15173171.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13743-7 [9354646.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1041-50 [10515227.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):549-61 [16783165.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Jun;4(6):362-74 [17534392.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] Hum Mutat. 2009 Jan;30(1):7-11 [19117336.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):417-24 [10667596.001]
  • (PMID = 19435942.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6618
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 1.1.1.41 / Isocitrate Dehydrogenase
  • [Other-IDs] NLM/ PMC2743214; NLM/ UKMS28703
  •  go-up   go-down


66. Durmaz R, Vural M, Işildi E, Coşan E, Ozkara E, Bal C, Ciftçi E, Arslantaş A, Atasoy MA: Efficacy of prognostic factors on survival in patients with low grade glioma. Turk Neurosurg; 2008 Oct;18(4):336-44
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of prognostic factors on survival in patients with low grade glioma.
  • AIM: In this report, we aim to determine the prognostic factors influencing the length of survival in patients with low-grade gliomas.
  • The diagnoses of the patients were histopathologically verified as low-grade glioma(LGG).
  • The medical records of the patients were reviewed for age, gender, tumor locations, extent of resection, and presence of seizure, the neurological status as defined by the Karnofsky Performance Scale (KPS) and radiotherapy treatment after surgery as possible prognostic factors.
  • Median survival time was 216+/-78.52 months for astrocytoma Grade I; 115+/-8.22 months for astrocytoma Grade II, and 242+/-76.36 months for oligodendroglioma.
  • Young age, histology subtype (oligodendroglioma) and preoperative KPS were determined to have positive influence on survival according to Log Rank Test.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / pathology. Glioma / mortality. Glioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aging. Astrocytoma / mortality. Astrocytoma / pathology. Astrocytoma / surgery. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgical Procedures. Oligodendroglioma / mortality. Oligodendroglioma / pathology. Oligodendroglioma / surgery. Prognosis. Reoperation. Retrospective Studies. Seizures / etiology. Survival. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19107679.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


67. Leighton C, Fisher B, Macdonald D, Stitt L, Bauman G, Cairncross J: The dose-volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection. J Neurooncol; 2007 Apr;82(2):165-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The dose-volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection.
  • PURPOSE: To evaluate the hypothesis that adults with partially resected (PR<50% resection) supratentorial low-grade glioma (LGG) benefit from higher doses of radiation.
  • METHODS: Patients receiving post-operative radiation for WHO grade I-II LGG at the University of Western Ontario between 1979 and 2001 were studied.
  • CONCLUSIONS: The outcome for patients with LGG is dependent on extent of tumor resection and radiation dose.
  • Future trials on therapeutic strategies for LGG should consider stratification of patients by extent of tumor resection.
  • [MeSH-major] Astrocytoma / radiotherapy. Oligodendroglioma / radiotherapy. Supratentorial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurooncol. 2007 Dec;85(3):357
  • (PMID = 17357830.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


68. Flannery T, Cawley D, Zulfiger A, Alderazi Y, Heffernan J, Brett F, Farrell M, O'Brien DF: Familial occurrence of oligodendroglial tumours. Br J Neurosurg; 2008 Jun;22(3):436-8
MedlinePlus Health Information. consumer health - Family Issues.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial occurrence of oligodendroglial tumours.
  • Two non-identical brothers were diagnosed with anaplastic oligoastrocytoma within 4 months of each other and a maternal grandmother was diagnosed with oligodendroglioma 21 years previously.
  • Familial clustering of oligodendrogliomas is rare.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Family. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18568735.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Zustovich F, Della Puppa A, Scienza R, Anselmi P, Furlan C, Cartei G: Metastatic oligodendrogliomas: a review of the literature and case report. Acta Neurochir (Wien); 2008 Jul;150(7):699-702; discussion 702-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic oligodendrogliomas: a review of the literature and case report.
  • Oligodendroglioma cells are detectable in the cerebro-spinal fluid in up to 14% of patients [10] and cerebellar and/or spinal cord involvement is a well known phenomenon [3].
  • Distant spread of oligodendroglioma is exceptional, probably due to the presence of the blood-brain barrier, the absence of lymphatic vessels and the short survival of patients.
  • This review was performed using NCBI-PubMed and "oligodendroglioma, oligodendrogliomas, metastatic, metastasis, metastases, extraneural", in different combinations, as key words and reviewing the bibliography of the consequent selected articles.
  • New therapeutic approaches are prolonging the overall survival of patients with primitive brain tumours and in particular of those with high grade oligodendroglioma which is a chemo-sensitive disease.
  • [MeSH-major] Brain Neoplasms / pathology. Liver Neoplasms / secondary. Occipital Lobe. Oligodendroglioma / secondary. Parietal Lobe
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Neurochir (Wien). 2009 Aug;151(8):987 [19424658.001]
  • (PMID = 18548193.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 29
  •  go-up   go-down


70. Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta M: Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg; 2008 Nov;109(5):835-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial.
  • OBJECT: In 1998, the Radiation Therapy Oncology Group initiated a Phase II study of observation for adults < 40 years old with cerebral low-grade glioma who underwent a neurosurgeon-determined gross-total resection (GTR).
  • METHODS: Patient eligibility criteria included the presence of a World Health Organization Grade II astrocytoma, oligodendroglioma, or mixed oligoastrocytoma confirmed histologically; age 18-39 years; Karnofsky Performance Scale score > or = 60; Neurologic Function Scale score < or = 3; supratentorial tumor location; neurosurgeon-determined GTR; and pre- and postoperative MR imaging with contrast enhancement available for central review by the principal investigator.
  • Prognostic factors analyzed for their contribution to patient overall survival, progression-free survival (PFS), and tumor recurrence included age, sex, Karnofsky Performance Scale score, Neurologic Function Scale score, histological type, contrast enhancement on preoperative MR imaging, preoperative tumor diameter, residual disease based on postoperative MR imaging, and baseline Mini-Mental State Examination score.
  • 1) preoperative tumor diameter > or = 4 cm;.
  • 2) astrocytoma/oligoastrocytoma histological type; and 3) residual tumor > or = 1 cm according to MR imaging.
  • CONCLUSIONS: These data suggest that young adult patients with low-grade glioma who undergo a neurosurgeon-determined GTR have a > 50% risk of tumor progression 5-years postoperatively, warranting close follow-up and consideration for adjuvant treatment.

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1153-60 [15001258.001]
  • [Cites] J Neurosurg. 2003 Jun;98(6):1165-9 [12816258.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):856-69 [8334640.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1784-91 [8082081.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):590-5 [7674006.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):85-101 [9210055.001]
  • [Cites] Neurosurgery. 2005;56(1):130-7; discussion 138 [15617595.001]
  • [Cites] JAMA. 2005 Feb 2;293(5):557-64 [15687310.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1227-33 [15690327.001]
  • [Cites] Lancet. 2005 Sep 17-23;366(9490):985-90 [16168780.001]
  • [Cites] Neurochirurgie. 2005 Sep;51(3-4 Pt 2):254-9 [16292169.001]
  • [Cites] Radiology. 2006 May;239(2):506-13 [16641355.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):392-401 [16648043.001]
  • [Cites] Acta Neurochir Suppl. 2006;98:87-95 [17009705.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Neuroradiology. 2001 Feb;43(2):129-33 [11326557.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1254-64 [12128127.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):663-8 [2921165.001]
  • (PMID = 18976072.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA32115; United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA37422; United States / NCI NIH HHS / CA / U10 CA037422; United States / NCI NIH HHS / CA / U10 CA021661; United States / NCI NIH HHS / CA / U10 CA032115
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS521858; NLM/ PMC3833272
  •  go-up   go-down


71. Iida M, Tsujimoto S, Nakayama H, Yagishita S: Ultrastructural study of neuronal and related tumors in the ventricles. Brain Tumor Pathol; 2008;25(1):19-23
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We analyzed intraventricular tumors, including central neurocytoma, oligodendroglioma, cerebral neuroblastoma, and cerebellar neuroblastoma, the neuronal characters of which were established based on their ultrastructural findings, except for oligodendroglioma.
  • Central neurocytoma and cerebellar neuroblastoma showed synaptic formation, and cerebral neuroblastoma possessed immature neurites.
  • Oligodendroglioma showed similar structures to that of a normal oligodendrocyte.
  • [MeSH-major] Cerebral Ventricle Neoplasms / ultrastructure. Neuroblastoma / ultrastructure. Neurocytoma / ultrastructure. Oligodendroglioma / ultrastructure
  • [MeSH-minor] Adult. Child, Preschool. Female. Humans. Infant. Male. Microscopy, Electron, Transmission

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18415662.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


72. Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y, Siegal T: Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer; 2006 Apr 15;106(8):1759-65
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
  • BACKGROUND: Loss of heterozygosity (LOH) on chromosomes 1p and 19q has been associated with chemosensitivity and improved prognosis in patients with oligodendrogliomas.
  • Recent studies demonstrated that temozolomide (TMZ), an oral alkylating agent, has efficacy in the treatment of patients with progressive, low-grade oligodendroglioma (LGO).
  • METHODS: Adult patients with magnetic resonance imaging (MRI) findings and/or clinical deterioration compatible with progressive LGO were eligible for the study if they were radiotherapy-naive.
  • Clinical and MRI data were used to evaluate outcomes, and Kaplan-Meier estimates were used to assess the median time to tumor progression (TTP).
  • The 1p/19q status was analyzed from paired tumor-blood DNA samples using polymerase chain reaction-based microsatellite analysis.
  • MGMT protein expression was estimated semiquantitatively by immunohistochemistry using paraffin embedded tumor sections.
  • RESULTS: There were 28 patients who received treatment, and the median time from diagnosis to tumor progression was 33.5 months.
  • The authors suggest the possible use of MGMT immunostaining as a surrogate marker for predicting tumor chemosensitivity.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Loss of Heterozygosity. O(6)-Methylguanine-DNA Methyltransferase / analysis. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Repair. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16541434.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


73. Volavsek M, Lamovec J, Popović M: Extraneural metastases of anaplastic oligodendroglial tumors. Pathol Res Pract; 2009;205(7):502-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraneural metastases of anaplastic oligodendroglial tumors.
  • According to the literature, they tend to appear in glioblastoma patients, but are exceptionally rare in anaplastic oligodendroglioma.
  • We report on an anaplastic oligodendroglioma and an anaplastic oligoastrocytoma that metastasized to cervical lymph nodes and bones.
  • Fine needle aspiration biopsy (FNAB) of the cervical lymph node prior to neck dissection suggested a possible metastatic primitive neuroepithelial tumor.
  • Our two cases reconfirm a rare but definite ability not only of glioblastoma but also of anaplastic oligodendroglioma, namely to metastasize to extraneural sites.
  • It is important to bear this in mind, particularly in cases when the history of primary brain tumor is unavailable.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology. Femoral Neoplasms / secondary. Neoplasm Recurrence, Local. Oligodendroglia / pathology. Oligodendroglioma / secondary. Sacrum / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Cranial Irradiation. Craniotomy. Fatal Outcome. Female. Humans. Lymphatic Metastasis. Middle Aged. Radiotherapy, Adjuvant. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410385.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


74. Wolff DL, Naruse R, Gold M: Nonopioid anesthesia for awake craniotomy: a case report. AANA J; 2010 Feb;78(1):29-32
Hazardous Substances Data Bank. PROPOFOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Awake craniotomy is becoming more popular as a neurosurgical technique that allows for increased tumor resection and decreased postoperative neurologic morbidity.
  • An ASA class II, 37-year-old man with recurrent oligodendroglioma presented for repeated craniotomy.
  • An awake craniotomy was planned to allow for intraoperative testing for maximum tumor resection and avoidance of neurologic morbidity.
  • Following exposure of brain tissue, propofol infusion was discontinued to allow for patient cooperation during the procedure.
  • Speech, motor, and sensory testing occurred during tumor resection until resection stopped after onset of weakness in the right arm.
  • [MeSH-minor] Adult. Brain Neoplasms. Humans. Male. Oligodendroglioma. Propofol / administration & dosage

  • MedlinePlus Health Information. consumer health - Anesthesia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20977126.001).
  • [ISSN] 0094-6354
  • [Journal-full-title] AANA journal
  • [ISO-abbreviation] AANA J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anesthetics, Intravenous; YI7VU623SF / Propofol
  •  go-up   go-down


75. Spampinato MV, Smith JK, Kwock L, Ewend M, Grimme JD, Camacho DL, Castillo M: Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol; 2007 Jan;188(1):204-12
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors.
  • OBJECTIVE: The purpose of this study was to determine whether perfusion-weighted imaging (PWI) and proton MR spectroscopy (MRS) are useful in differentiating high- and low-grade oligodendroglial tumors.
  • MATERIALS AND METHODS: PWI and MRS studies of 22 patients with histologically proven oligodendroglioma or oligoastrocytoma (13 low-grade and nine anaplastic tumors) were retrospectively reviewed.
  • RESULTS: Relative cerebral blood volume ratios were significantly different (p = 0.004) between low-grade (1.61 +/- 1.20) and high-grade tumors (5.45 +/- 1.96).
  • The optimal relative cerebral blood volume ratio cutoff value in identification of anaplastic oligodendroglial tumors was 2.14.
  • Analysis of MRS data showed significantly higher Cho/Cr ratios (p = 0.002) in high-grade than in low-grade tumors.
  • A Cho/Cr ratio cutoff value of 2.33 had the highest accuracy in identification of high-grade tumors.
  • CONCLUSION: Relative cerebral blood volume measurement and MRS are helpful in differentiating low-grade from anaplastic oligodendroglial tumors.
  • [MeSH-major] Blood Volume. Brain Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Magnetic Resonance Spectroscopy / methods. Oligodendroglioma / diagnosis. Protons
  • [MeSH-minor] Adult. Aged. Blood Volume Determination / methods. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179366.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


76. Ramos TC, Figueredo J, Catala M, González S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, Leonard I, Torres O, Marinello P, Pérez R, Lage A: Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther; 2006 Apr;5(4):375-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.
  • The poor prognosis of patients with high-grade glioma has led to the search for new therapeutic strategies.
  • In order to evaluate safety, immunogenicity and preliminary efficacy of h-R3 in newly diagnosed high-grade glioma patients, we conducted a Phase I/II trial.
  • Tumor types were: glioblastoma (GB) (16 patients), anaplastic astrocytoma (AA) (12 patients) and anaplastic oligodendroglioma (AO) (1 patient).
  • No evidences of grade 3/4 adverse events were detected.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Astrocytoma / therapy. Glioblastoma / therapy. Glioma / pathology. Glioma / therapy. Oligodendroglioma / therapy. Receptor, Epidermal Growth Factor / immunology
  • [MeSH-minor] Adult. Aged. Antibodies / chemistry. Antibodies, Monoclonal, Humanized. Female. Humans. Male. Middle Aged. Organotechnetium Compounds. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • Genetic Alliance. consumer health - Glioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575203.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 99mTc-hR3 monoclonal antibody; 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Organotechnetium Compounds; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


77. Ozkul A, Meteoglu I, Tataroglu C, Akyol A: Primary diffuse leptomeningeal oligodendrogliomatosis causing sudden death. J Neurooncol; 2007 Jan;81(1):75-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary diffuse leptomeningeal oligodendrogliomatosis is a rare malignancy of central nervous system without evidence of a primary intraparenchymal focus.
  • Autopsy revealed a nodular lesion at the level of thoracal 10 vertebra and diffuse oligodendroglioma throughout the leptomeninges of the brain and spine without intraaxial focus.
  • [MeSH-major] Death, Sudden / etiology. Meningeal Neoplasms / complications. Oligodendroglioma / complications
  • [MeSH-minor] Adult. Central Nervous System Neoplasms / complications. Central Nervous System Neoplasms / pathology. Fatal Outcome. Female. Humans. Paraplegia. Thoracic Vertebrae

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17077938.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


78. Sepulveda Sanchez JM, Martinez Montero JC, Diez-Lobato R, Hernandez-Lain A, Cabello A, Ramos A, Gonzalez Leon P, Ricoy Campo JR: Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival--clinical, radiological and pathologic long-term follow-up analysis. Clin Neuropathol; 2009 Jan-Feb;28(1):11-20
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival--clinical, radiological and pathologic long-term follow-up analysis.
  • BACKGROUND: The clinical course of oligodendroglial tumors is variable and there is a lack of consensus with regard to precisely diagnose which minimal criteria are required to make a diagnosis of a high-grade oligodendrial tumor.
  • The aims of the present study are to assess pathologic factors with prognostic significance, in addiction to clinical and neuroradiologic variables, in an attempt to identify reproducible histological parameters that are useful for classification of oligodendroglial tumors.
  • METHODS: 80 oligodendroglial tumors diagnosed between 1977 and 2004 were analyzed.
  • To make a diagnosis of anaplastic tumor we used reproducible parameters: endothelial proliferation, high cellularity, increased mitotic activity and necrosis.
  • RESULTS: The histologic diagnosis was low-grade oligodendroglioma in 35 patients (43.75%), anaplastic oligodendroglioma in 23 patients (28.75%), low-grade oligoastrocytoma in 11 patients (13.75%) and anaplastic oligoastrocytoma in 11 patients (13.75%).
  • The median overall survival of oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytoma and anaplastic oligoastrocytoma was 148, 105, 47 and 7 months, respectively (p < 0.0001).
  • Multivariate analysis revealed that age, Karnofsky performance status, histological grade and histological diagnosis (oligodendroglioma vs. oligoastrocytoma) were independently associated with survival.
  • CONCLUSIONS: Clear cut histopathological criteria (endothelial proliferation, high cellularity, mitotic activity and necrosis) allow to establish different oligodendroglial tumor entities with distinct survival outcome.
  • [MeSH-major] Brain Neoplasms / classification. Brain Neoplasms / pathology. Oligodendroglioma / classification. Oligodendroglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Neuropathol. 2009 Mar-Apr;28(2):150
  • (PMID = 19216215.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


79. Xiong NX, Zhao HY, Zhang FC, He ZQ: Negative correlation of Nogo-A with the malignancy of oligodendroglial tumor. Neurosci Bull; 2007 Jan;23(1):41-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Negative correlation of Nogo-A with the malignancy of oligodendroglial tumor.
  • OBJECTIVE: Nogo-A is an axon regeneration inhibitor, and its function in central nervous system (CNS) is still unknown.
  • The present study is to explore the relationship between the expression of Nogo-A and the malignancy of oligodendroglial tumors in patients.
  • METHODS: Tumor tissue samples with different malignancy grade were obtained from the hospitals.
  • The samples used for detection had been diagnosed as oligodendroglial tumors (oligodendroglioma or anaplastic oligodendroglioma).
  • The correlation test between the Nogo-A expression and the morphological changes (the percentages of atypical cells and mitotic cells in the tumors) related to the malignancy of tumor tissues was performed.
  • RESULTS: There was significant negative correlation between the Nogo-A expression and the morphological change of tumor tissues according to immunohistochemistry.
  • Western-blot analysis also indicated that the gray value of Nogo-A protein band in the oligodendroglioma group was significantly higher than that in the anaplastic oligodendroglioma group.
  • CONCLUSION: Nogo-A expression was negatively correlated with the malignancy grade of oligodendroglial tumors.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Myelin Proteins / metabolism. Oligodendroglioma / diagnosis. Oligodendroglioma / metabolism
  • [MeSH-minor] Adult. Down-Regulation / physiology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mitotic Index. Neoplasm Invasiveness / diagnosis. Nogo Proteins. Predictive Value of Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2002 May 1;22(9):3553-67 [11978832.001]
  • [Cites] J Neurosci. 2003 Jul 2;23 (13):5393-406 [12843238.001]
  • [Cites] Oncogene. 2001 Jul 5;20(30):3929-36 [11494121.001]
  • [Cites] J Mol Neurosci. 2005;25(1):1-6 [15781961.001]
  • [Cites] J Cell Physiol. 2003 Aug;196 (2):312-8 [12811824.001]
  • [Cites] Nature. 2000 Jan 27;403(6768):434-9 [10667796.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19280-5 [12639960.001]
  • [Cites] Nature. 2000 Jan 27;403(6768):439-44 [10667797.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):149-58 [9426071.001]
  • [Cites] J Neurochem. 2004 Sep;90(5):1156-62 [15312170.001]
  • [Cites] Oncogene. 2003 Mar 6;22(9):1390-9 [12618765.001]
  • [Cites] Oncogene. 2000 Nov 23;19(50):5736-46 [11126360.001]
  • [Cites] Biochem J. 2005 Oct 15;391(Pt 2):433-40 [16095439.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):2977-87 [15021917.001]
  • [Cites] Apoptosis. 2003 Jan;8(1):5-9 [12510146.001]
  • (PMID = 17592524.001).
  • [ISSN] 1673-7067
  • [Journal-full-title] Neuroscience bulletin
  • [ISO-abbreviation] Neurosci Bull
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Myelin Proteins; 0 / Nogo Proteins; 0 / RTN4 protein, human
  •  go-up   go-down


80. Moriguchi S, Yamashita A, Marutsuka K, Yoneyama T, Nakano S, Wakisaka S, Nabeshima K, Asada Y: Atypical extraventricular neurocytoma. Pathol Int; 2006 Jan;56(1):25-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extraventricular neurocytoma (EVN) is a rare brain tumor that poses diagnostic difficulty.
  • A well-circumscribed lesion (3.0 x 3.0 x 3.0 cm) in the right parietal lobe showed diffuse proliferation of monotonous tumor cells with perinuclear clearing within a delicate fibrillary matrix similar to neuropil.
  • Tumor also showed vascular proliferation and high mitotic activity.
  • Immunohistochemically, these tumor cells were strongly positive for synaptophysin both in the neuropil and in the perinuclear cytoplasm, and were negative for glial fibrillary acidic protein and Olig2.
  • EVN should be considered as a candidate in the differential diagnosis of parenchymal brain tumor, especially oligodendroglioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neurocytoma / diagnosis. Parietal Lobe
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Middle Aged. Synaptophysin / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398676.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Synaptophysin
  •  go-up   go-down


81. Schomas DA, Laack NN, Rao RD, Meyer FB, Shaw EG, O'Neill BP, Giannini C, Brown PD: Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol; 2009 Aug;11(4):437-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic.
  • The purpose of this study was to evaluate long-term survival in patients with nonpilocytic low-grade gliomas (LGGs).
  • Records of 314 adult patients with nonpilocytic LGGs diagnosed between 1960 and 1992 at the Mayo Clinic, Rochester, Minnesota, were retrospectively reviewed.
  • Operative pathology revealed pure astrocytoma in 181 patients (58%), oligoastrocytoma in 99 (31%), and oligodendroglioma in 34 (11%).
  • Adverse prognostic factors for OS identified by multivariate analysis were tumor size 5 cm or larger, pure astrocytoma histology, Kernohan grade 2, undergoing less than rSTR, and presentation with sensory motor symptoms.
  • Statistically significant adverse prognostic factors for PFS by multivariate analysis were only tumor size 5 cm or larger and undergoing less than rSTR.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 May;64(5):581-7 [9598670.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3129-40 [9294476.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1227-33 [15690327.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Lancet. 2005 Sep 17-23;366(9490):985-90 [16168780.001]
  • [Cites] J Neurooncol. 2006 Sep;79(2):153-7 [16855865.001]
  • [Cites] Neurology. 2007 May 22;68(21):1831-6 [17515545.001]
  • [Cites] Brain Pathol. 2007 Jul;17(3):308-13 [17598823.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Clin Oncol. 2008 Mar 10;26(8):1338-45 [18323558.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):218-24 [21549518.001]
  • [Cites] Ann Neurol. 1992 Apr;31(4):431-6 [1586143.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9 [10571199.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1442-8 [10751254.001]
  • [Cites] Strahlenther Onkol. 2000 Jun;176(6):259-64 [10897252.001]
  • [Cites] Neurology. 2001 Mar 13;56(5):618-23 [11245713.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):735-45 [11702861.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):305-12 [12892238.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):117-25 [15093907.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Cancer. 1975 Nov;36(5):1681-9 [172217.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Br J Clin Pharmacol. 1982 Sep;14(3):325-31 [6751362.001]
  • [Cites] Neurosurgery. 1987 Jun;20(6):975-82 [3614580.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Oct;15(4):837-41 [3141317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Mar;16(3):663-8 [2921165.001]
  • [Cites] J Neurosurg. 1989 Jun;70(6):853-61 [2715812.001]
  • [Cites] Neurosurgery. 1989 May;24(5):686-92 [2716976.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):487-93 [2552044.001]
  • [Cites] Arch Neurol. 1989 Nov;46(11):1238-9 [2818260.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):554-9 [8474646.001]
  • [Cites] W V Med J. 1993 Mar;89(3):102-5 [8475621.001]
  • [Cites] J Neurosurg. 1993 Jun;78(6):909-14 [8487073.001]
  • [Cites] Acta Neurochir (Wien). 1993;123(1-2):1-7 [8213272.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1937-45 [8137221.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1093-112 [7677836.001]
  • [Cites] Surg Neurol. 1995 Sep;44(3):208-21; discussion 221-3 [8545771.001]
  • [Cites] J Neurooncol. 1996 Feb;27(2):173-7 [8699240.001]
  • [Cites] Neurosurgery. 1996 May;38(5):872-8; discussion 878-9 [8727811.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]
  • [Cites] J Neurooncol. 1997 Feb;31(3):273-8 [9049856.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1294-301 [9193320.001]
  • [Cites] Neurology. 1999 Mar 10;52(4):867-9 [10078745.001]
  • (PMID = 19018039.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / P50 CA108961; United States / NCI NIH HHS / CA / P30 CA15083
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2743224
  •  go-up   go-down


82. Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T: Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol; 2006 Sep;79(2):153-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial.
  • PURPOSE: Chemotherapy with alkylating agents is of proven efficacy in recurrent anaplastic oligodendroglioma (AO) with reported response rates ranging between 50% and 70%.
  • This study evaluated the response and time to tumor progression of newly diagnosed AO initially treated with TMZ.
  • Treatment was given every 28 days for 5 days at a starting dose of 200 mg/m2/d and was continued for 24 cycles unless toxicity or tumor progression required withdrawal of TMZ.
  • The objective response rate was 75%, and median time to tumor progression was 24 months.
  • TMZ was well tolerated with only two events of grade 3/4 hematological toxicity.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855865.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


83. Gonzales M, Dale S, Susman M, Nolan P, Ng WH, Maixner W, Laidlaw J: Dysembryoplastic neuroepithelial tumor (DNT)-like oligodendrogliomas or Dnts evolving into oligodendrogliomas: two illustrative cases. Neuropathology; 2007 Aug;27(4):324-30
Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysembryoplastic neuroepithelial tumor (DNT)-like oligodendrogliomas or Dnts evolving into oligodendrogliomas: two illustrative cases.
  • A review of dysembryoplastic neuroepithelial tumors (DNTs) in 14 patients over a 12-year period revealed four patients re-operated because of changes on magnetic resonance imaging (MRI) suggesting tumor recurrence or progression.
  • In the fourth patient, persistent DNT was surrounded by WHO grade 2 oligoastrocytoma.
  • In one of the other 10 patients, WHO grade 2 oligodendroglioma was present in white matter deep to and completely separate from a cortically based DNT.
  • Fluorescence in situ hybridization showed codeletion of 1p and 19q in both the DNT and oligodendroglioma and oligoastrocytoma components.
  • Deletions were not identified in any other tumor.
  • These two unusual tumors also raise the possibility that rare DNTs may evolve into oligodendroglioma or oligoastrocytoma.
  • [MeSH-major] Neoplasms, Multiple Primary / pathology. Neoplasms, Neuroepithelial / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Astrocytoma / genetics. Astrocytoma / pathology. Astrocytoma / surgery. Chromosome Deletion. Electroencephalography. Female. Humans. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899685.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


84. Buccoliero AM, Arganini L, Ammannati F, Gallina P, Di Lorenzo N, Mennonna P, Taddei GL: Oligodendrogliomas lacking O6-methylguanine-DNA-methyltransferase expression. J Chemother; 2005 Jun;17(3):321-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendrogliomas lacking O6-methylguanine-DNA-methyltransferase expression.
  • We evaluated the immunohistochemical MGMT expression in 28 consecutive oligodendroglial tumors (21 oligodendrogliomas, 5 mixed oligoastrocytomas, and 2 glioblastomas with prominent oligodendroglial features; 13 treated with CCNU) and compared it with that of 13 glioblastomas.
  • Twenty-six (93%) oligodendroglial tumors were MGMT-negative, 2 (7%) were MGMT-positive.
  • Twelve (92%) patients treated with CCNU had MGMT-negative lesions and their median survival was 73 months; 1 patient had an MGMT-positive oligodendroglioma and is alive at 28 months.
  • The lower MGMT expression in oligodendroglial tumors compared to glioblastomas (P < 0.05), which have different chemosensitivity, suggests a possible role of MGMT in the determination of chemoresistance.
  • Nevertheless, the heterogeneous outcome of our MGMT-negative oligodendroglial tumors treated with CCNU, indicates that MGMT expression alone is insufficient to predict the response to alkylating drugs, presumably because of the numerous mechanisms involved.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Brain Neoplasms / genetics. DNA Repair. Gene Expression Profiling. Glioblastoma / genetics. Nitrosourea Compounds / pharmacology. O(6)-Methylguanine-DNA Methyltransferase / analysis. O(6)-Methylguanine-DNA Methyltransferase / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Drug Resistance, Neoplasm. Female. Humans. Immunohistochemistry. Male. Middle Aged. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038527.001).
  • [ISSN] 1120-009X
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


85. Sakurada K, Akasaka M, Kuchiki H, Saino M, Mori W, Sato S, Nakazato Y, Kayama T: A rare case of extraventricular neurocytoma. Brain Tumor Pathol; 2007;24(1):19-23
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 1978, an 18-year-old woman was treated for right frontal oligodendroglioma.
  • Eighteen years later (in 1996), recurrence of tumor in the fourth ventricle was noted and was treated with gamma-knife radiotherapy.
  • The tumor shrunk transiently, but 7 years later (in 2004), MRI study demonstrated a second recurrence and ventricular dissemination.
  • Partial removal was performed, and histological examination revealed that tumor cells had round or oval nuclei with halos.
  • Despite postoperative whole-brain radiotherapy to a total dose of 30 Gy, the tumor progressed, and she died at 4 months after the second surgery.
  • [MeSH-major] Brain Neoplasms / pathology. Diagnostic Errors. Neoplasm Recurrence, Local / pathology. Neuroblastoma / pathology. Neurocytoma / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Female. Fourth Ventricle / pathology. Frontal Lobe / pathology. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095140.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


86. Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M, Goldbrunner R, Krex D, Steinbach JP, Ostertag CB, Loeffler M, Pietsch T, von Deimling A, German Glioma Network: Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res; 2007 Dec 1;13(23):6933-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
  • PURPOSE: The combined loss of genetic material on chromosomes 1p and 19q is strongly associated with favorable outcome in patients with WHO grade 3 anaplastic oligodendroglial tumors.
  • The prognostic value of 1p/19q loss in WHO grade 2 oligodendroglial tumors is less well defined.
  • EXPERIMENTAL DESIGN: Seventy-six patients with oligodendroglioma (n = 33), oligoastrocytoma (n = 30), anaplastic oligodendroglioma (n = 6), or anaplastic oligoastrocytoma (n = 7) were identified who had not received radiotherapy or chemotherapy after their first operation until the end of follow-up or until the first progression and had tissue for 1p/19q status available.
  • CONCLUSIONS: Combined 1p/19q loss is not a sensitive prognostic biomarker in patients with oligodendroglial tumors who do not receive radiotherapy or chemotherapy.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Deletion. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Astrocytoma / pathology. Biomarkers, Tumor / genetics. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056167.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


87. Järvelä S, Parkkila S, Bragge H, Kähkönen M, Parkkila AK, Soini Y, Pastorekova S, Pastorek J, Haapasalo H: Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer; 2008;8:1
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase IX in oligodendroglial brain tumors.
  • METHODS: This study was set out to investigate the role of CA IX in a series of 86 oligodendroglial brain tumors (71 primary and 15 recurrent; 48 pure oligodendrogliomas and 40 mixed oligoastrocytomas).
  • In Cox multivariate analysis CA IX expression, patient age and histological component (pure oligodendroglioma vs. mixed oligoastrocytoma) showed independent prognostic values (p = 0.009, p = 0.003 and p = 0.022, respectively), CA IX positivity predicting poorer outcome.
  • CONCLUSION: CA IX was proved to be an independent prognostic indicator in oligodendroglial brain tumors, and it also correlates reversely with cell proliferation.
  • It may have a role in the biology of oligodendrogliomas, and most interestingly, as it is mainly expressed in tumor tissue, CA IX could serve as a target molecule for anticancer treatments.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Brain Neoplasms / enzymology. Carbonic Anhydrases / metabolism. Oligodendroglioma / enzymology
  • [MeSH-minor] Adult. Cell Proliferation. Follow-Up Studies. Humans. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6567-71 [15475445.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):398-408 [9024293.001]
  • [Cites] Cancer Res. 1982 May;42(5):1955-61 [7066906.001]
  • [Cites] Am J Med. 1991 Sep 30;91(3C):14S-22S [1928205.001]
  • [Cites] Virology. 1992 Apr;187(2):620-6 [1312272.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3113-7 [8464931.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):268-74 [8486430.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Aug;16(4):261-8 [7524516.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Am J Pathol. 1998 Jul;153(1):279-85 [9665489.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1197-207 [15752902.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7259-66 [16103077.001]
  • [Cites] Histol Histopathol. 2005 Oct;20(4):1173-7 [16136500.001]
  • [Cites] Bioorg Med Chem Lett. 2005 Nov 1;15(21):4872-6 [16165351.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):465-75 [16212811.001]
  • [Cites] Biochem J. 2005 Nov 15;392(Pt 1):83-92 [16083424.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] J Neurooncol. 2006 Apr;77(2):131-40 [16292483.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 [10598694.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1750-7 [11410516.001]
  • [Cites] Mol Hum Reprod. 2001 Jul;7(7):611-6 [11420383.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5262-7 [11431368.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2001;30:421-55 [11441809.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):165-71 [11443623.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3660-8 [11504747.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6394-9 [11522632.001]
  • [Cites] Neurology. 2001 Oct 9;57(7):1278-81 [11591848.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7992-8 [11691824.001]
  • [Cites] J Hepatol. 2001 Nov;35(5):643-9 [11690711.001]
  • [Cites] J Neurooncol. 2001 Oct;55(1):29-37 [11804280.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1205-12 [11861405.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Apr;28(2):89-94 [11972795.001]
  • [Cites] Med Res Rev. 2003 Mar;23(2):146-89 [12500287.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Brain Pathol. 2003 Apr;13(2):155-64 [12744469.001]
  • [Cites] Int J Cancer. 2003 Jul 20;105(6):873-81 [12767076.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Jun 15;167(12):1600-19 [12796054.001]
  • [Cites] Exp Cell Res. 2003 Nov 1;290(2):332-45 [14567991.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23 [14684331.001]
  • [Cites] Int J Oncol. 2004 Apr;24(4):995-1004 [15010840.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Feb 23;14(4):869-73 [15012984.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6160-5 [15342400.001]
  • [Cites] Annu Rev Biochem. 1995;64:375-401 [7574487.001]
  • [Cites] J Enzyme Inhib Med Chem. 2004 Jun;19(3):199-229 [15499993.001]
  • (PMID = 18173856.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ PMC2245965
  •  go-up   go-down


88. Oshiro S, Tsugu H, Komatsu F, Ohmura T, Ohta M, Sakamoto S, Fukushima T, Inoue T: Efficacy of temozolomide treatment in patients with high-grade glioma. Anticancer Res; 2009 Mar;29(3):911-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of temozolomide treatment in patients with high-grade glioma.
  • BACKGROUND: Numerous studies have reported the clinical efficacy of temozolomide (TMZ) treatment for high-grade glioma, but information on Japanese populations has been limited.
  • PATIENTS AND METHODS: The subjects comprised ten patients with high-grade glioma [glioblastoma multiforme (GBM), n=3, gliosarcoma (GS), n=1, anaplastic oligodendroglioma (AO), n=3, anaplastic mixed oligoastrocytoma (AOA), n=1, and anaplastic ependymoma (AE), n=2].
  • As second- or third-line chemotherapy, patients received TMZ for recurrence or tumor progression.
  • As combination therapy, the local administration of tumor necrosis factor-alpha and the addition of carboplatin and etoposide were included for three patients during the course of oral TMZ treatment.
  • One of the patients receiving combination therapy has continued to show shrinkage of the relapsed tumor.
  • Despite prior radio- and chemotherapy, most patients experienced only grade 1-2 hematotoxicity that was well-controlled by conservative therapy.
  • CONCLUSION: TMZ chemotherapy is effective for the treatment of high-grade glioma in some patients without serious toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Gliosarcoma / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Treatment Outcome. Tumor Necrosis Factor-alpha / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414327.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


89. Shah MN, Leonard JR, Perry A: Rosette-forming glioneuronal tumors of the posterior fossa. J Neurosurg Pediatr; 2010 Jan;5(1):98-103
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle is a rare, recently described WHO Grade I neoplasm.
  • The original diagnoses included pilocytic astrocytoma, ependymoma, cerebellar dysembryoplastic neuroepithelial tumor (DNT), and oligodendroglioma.
  • These cases expand the known clinical and histological spectrum of this rare tumor type.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / surgery. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / surgery. Cerebral Ventricle Neoplasms / diagnosis. Cerebral Ventricle Neoplasms / surgery. Cranial Fossa, Posterior. Ependymoma / diagnosis. Ependymoma / surgery. Magnetic Resonance Imaging. Neuroectodermal Tumors, Primitive / diagnosis. Oligodendroglioma / diagnosis. Oligodendroglioma / surgery. Skull Base Neoplasms / diagnosis. Skull Base Neoplasms / surgery. Teratoma / diagnosis. Teratoma / surgery
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043744.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


90. Lebrun C, Fontaine D, Bourg V, Ramaioli A, Chanalet S, Vandenbos F, Lonjon M, Fauchon F, Paquis P, Frenay M: Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol; 2007 Apr;14(4):391-8
Hazardous Substances Data Bank. PROCARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy.
  • Based on studies relating to anaplastic oligodendroglioma (OG) chemosensitivity and benefit of time to progression or overall survival, chemotherapy for pure OG has been proposed.
  • Several studies have reported the efficacy of various chemotherapeutic agents in a small number of patients with low-grade gliomas, e.g. pure astrocytomas, OG or mixed histologies.
  • We report the outcome of 33 consecutive patients with pure low-grade OG diagnosed between 1990 and 2006 systematically treated for residual or non-removable tumor with PCV chemotherapy regimen as the front-line treatment after surgery.
  • All the tumors were low grade (grade II) pure OG according to the WHO classification.
  • Response was evaluated by clinical assessment and brain magnetic resonance imaging.
  • Up-front chemotherapy with PCV regimen is a good treatment for symptomatic pure low-grade OG, as it increases the number of progression-free patients and time to progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Disease Progression. Disease-Free Survival. Female. Humans. Lomustine / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Procarbazine / therapeutic use. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388986.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; PCV protocol
  •  go-up   go-down


91. Seol HJ, Kim JE, Wang KC, Kim SK, Seo JS, Park SH, Jung HW: The pattern of gene expression and possible relation of steroidogenic genes in oligodendroglial tumors. Int J Oncol; 2009 Jan;34(1):181-90
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pattern of gene expression and possible relation of steroidogenic genes in oligodendroglial tumors.
  • StAR is expressed at a very low level in the white matter of the normal human brain, but is highly expressed in several brain neoplasms including oligodendroglioma (OD).
  • The aim of this study was to identify the different patterns of gene expression low-grade OD and high-grade OD.
  • There was a difference in genetic expression between low- and high-grade ODs.
  • The expression of such genes showed a tendency either of decreasing or mildly increasing, in high-grade ODs, compared with low-grade ODs.
  • Real-time PCR showed that expression of StAR was relatively low in high-grade ODs, in comparison with low-grade ODs.
  • The pattern of expression between low- and high-grade ODs can differ.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / genetics. Gene Expression Profiling. Oligodendroglioma / genetics. Steroids / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / metabolism. Brain / pathology. Child. Child, Preschool. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Oligonucleotide Array Sequence Analysis. Phosphoproteins / genetics. Phosphoproteins / metabolism. RNA, Neoplasm. Transcription, Genetic. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082489.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Phosphoproteins; 0 / RNA, Neoplasm; 0 / Steroids; 0 / steroidogenic acute regulatory protein
  •  go-up   go-down


92. Griffin CA, Burger P, Morsberger L, Yonescu R, Swierczynski S, Weingart JD, Murphy KM: Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol; 2006 Oct;65(10):988-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.
  • Deletions of portions of chromosomes 1p and 19q are closely associated with the oligodendroglioma histologic phenotype.
  • We report 5 cases (World Health Organization grade III) in which metaphase cytogenetics identified a derivative chromosome consisting of what appears to be the whole arms of 1q and 19p forming a der(1;19)(q10;p10).
  • Subsequent loss of the der(1;19)(p10;q10) then results in the simultaneous 1p and 19q loss observed in oligodendroglioma with retention of the der(1;19)(q10;p10) seen in these cases.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Oligodendroglioma / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Chromosome Aberrations. Chromosome Deletion. Female. Humans. In Situ Hybridization, Fluorescence. Loss of Heterozygosity. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17021403.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Deorah S, Lynch CF, Sibenaller ZA, Ryken TC: Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus; 2006;20(4):E1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001.
  • OBJECT: An increasing incidence of brain cancer has been reported for the last three decades.
  • In this study of brain cancer incidence and patient survival in the US, the authors attempt to update information on trends by examining data provided by the Surveillance, Epidemiology, and End Results (SEER) Program.
  • METHODS: Population-based data from the SEER Program were used to calculate the incidence of and survival rates for people with brain cancer.
  • The approximate Poisson method was used to calculate relative risks for brain cancer and to determine a 95% confidence interval.
  • The relative risks of brain cancer were 1.48 for men compared with women, 3.18 for elderly persons compared with young adults, 1.86 for Caucasian patients compared with African-American patients, and 1.35 for those in metropolitan counties compared with those in nonmetropolitan counties.
  • The incidence of brain cancer increased until 1987, when the annual percentage of change reversed direction, decreasing from 1.68 to 20.44%.
  • Rising trends were noticed for glioblastoma multiforme (GBM), oligodendroglioma, anaplastic astrocytoma, medulloblastoma, and mixed glioma, and falling trends were observed for astrocytoma not otherwise specified and malignant glioma.
  • CONCLUSIONS: Increased risk of brain cancer is associated with being male, Caucasian, elderly, and residing in a metropolitan county.
  • The incidence rate of brain cancer in the US is gradually declining, but the rising trend of GBM combined with its poor survival rate is disconcerting and needs further exploration.
  • [MeSH-major] Astrocytoma / epidemiology. Brain Neoplasms / epidemiology. Glioblastoma / epidemiology. Glioma / epidemiology. Medulloblastoma / epidemiology. Oligodendroglioma / epidemiology. Population Surveillance
  • [MeSH-minor] Adult. Age Distribution. Aged. Cohort Studies. Continental Population Groups / statistics & numerical data. Female. Humans. Incidence. Male. Middle Aged. Risk Factors. Rural Population / statistics & numerical data. SEER Program / statistics & numerical data. Sex Distribution. Survival Rate / trends. United States / epidemiology. Urban Population / statistics & numerical data

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16709014.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Zemanová Z, Kramar F, Babická L, Ransdorfová S, Melichercíková J, Hrabal P, Kozler P, Michalová K: Molecular cytogenetic stratification of recurrent oligodendrogliomas: utility of interphase fluorescence in situ hybridization (I-FISH). Folia Biol (Praha); 2006;52(3):71-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular cytogenetic stratification of recurrent oligodendrogliomas: utility of interphase fluorescence in situ hybridization (I-FISH).
  • In oligodendroglial brain tumours, losses of chromosomal material of the short arm of chromosome 1 and long arm of chromosome 19 have been shown to predict responsiveness to chemotherapy and prolonged patients' survival.
  • Therefore, the correct diagnosis of these genetic alterations in tumours of oligodendroglial origin is particularly important.
  • To detect deletions of 1p36 and/or 19q13.3 in oligodendroglial cells we used dual-colour I-FISH with locus-specific DNA probes.
  • We examined 16 patients with histologically proved oligodendrogliomas (5x oligodendroglioma, 9x anaplastic oligodendroglioma, 2x anaplastic oligoastrocytoma).
  • However, in six of them additional genetic alterations typical for high-grade astrocytoma were found, which could have negative influence on the prognosis.
  • A systematic molecular cytogenetic analysis may advance diagnosis, prognostic stratification, and targeted treatment of patients with brain tumours.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. In Situ Hybridization, Fluorescence. Interphase / physiology. Oligodendroglioma / diagnosis. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Cell Nucleus / metabolism. Chromosome Aberrations. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Pair 9 / genetics. DNA Probes / metabolism. Female. Genome, Human / genetics. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089917.001).
  • [ISSN] 0015-5500
  • [Journal-full-title] Folia biologica
  • [ISO-abbreviation] Folia Biol. (Praha)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / DNA Probes
  •  go-up   go-down


95. Tendulkar RD, Pai Panandiker AS, Wu S, Kun LE, Broniscer A, Sanford RA, Merchant TE: Irradiation of pediatric high-grade spinal cord tumors. Int J Radiat Oncol Biol Phys; 2010 Dec 01;78(5):1451-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irradiation of pediatric high-grade spinal cord tumors.
  • PURPOSE: To report the outcome using radiation therapy (RT) for pediatric patients with high-grade spinal cord tumors.
  • METHODS AND MATERIALS: A retrospective chart review was conducted that included 17 children with high-grade spinal cord tumors treated with RT at St. Jude Children's Research Hospital between 1981 and 2007.
  • The tumor diagnosis was glioblastoma multiforme (n = 7), anaplastic astrocytoma (n = 8), or anaplastic oligodendroglioma (n = 2).
  • Local tumor progression at 12 months (79% vs. 30%, p = 0.02) and median survival (13.1 vs. 27.2 months, p = 0.09) were worse for patients with glioblastoma multiforme compared with anaplastic astrocytoma or oligodendroglioma.
  • Three long-term survivors with World Health Organization Grade III tumors were alive with follow-up, ranging from 88-239 months.
  • CONCLUSIONS: High-grade spinal cord primary tumors in children have a poor prognosis.
  • [MeSH-major] Astrocytoma / radiotherapy. Oligodendroglioma / radiotherapy. Spinal Cord Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Glioblastoma / mortality. Glioblastoma / pathology. Glioblastoma / radiotherapy. Glioblastoma / surgery. Humans. Male. Prognosis. Radiotherapy Dosage. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] J Neurosurg. 1987 Apr;66(4):621-5 [3031241.001]
  • [Cites] Pediatr Neurosurg. 1999 Jan;30(1):1-5 [10202299.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Jul;30(7):489-94 [1701860.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):590-5 [7674006.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 May;27(5):254-8 [15891559.001]
  • [Cites] Neurosurgery. 2002 Aug;51(2):343-55; discussion 355-7 [12182772.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1005-11 [9719109.001]
  • [Cites] Arch Neurol. 1978 Apr;35(4):244-5 [205201.001]
  • [Cites] J Neurooncol. 1997 Jul;33(3):205-11 [9195492.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):845-50 [9531369.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):997-1007 [6349785.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3431-7 [16849758.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1397-403 [2542194.001]
  • [Cites] J Neurosurg. 1979 Oct;51(4):437-45 [479930.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1535-43 [8608540.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):497-504 [9241084.001]
  • [Cites] Spinal Cord. 2005 Sep;43(9):565-7 [15838531.001]
  • [Cites] Cancer. 1982 Aug 15;50(4):732-5 [7093908.001]
  • [Cites] Neurosurgery. 1991 Feb;28(2):302-6 [1847741.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1060-71 [16373081.001]
  • [Cites] J Neurosurg. 1996 Dec;85(6):1036-43 [8929492.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):727-33 [18687533.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):179-83 [15925999.001]
  • [Cites] Childs Nerv Syst. 2006 Jul;22(7):652-61 [16565851.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):323-8 [7673019.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):313-9 [16200343.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):403-7 [16609952.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2391-9 [9840540.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853-60 [15465203.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Neurosurg. 1998 Feb;88(2):215-20 [9452226.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):50-4 [2909688.001]
  • (PMID = 20346593.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


96. Xu M, See SJ, Ng WH, Arul E, Back MF, Yeo TT, Lim CC: Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery; 2005 May;56(5):919-26; discussion 919-26
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors.
  • OBJECTIVE: Oligodendroglial tumors form an uncommon, but distinct, subgroup of gliomas with longer survival, better treatment response, and characteristic genetic alterations.
  • Noninvasive grading of oligodendroglial tumors using functional and metabolic magnetic resonance imaging may be helpful in guiding the treatment approach and predicting malignant transformation of these tumors.
  • We used perfusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopic imaging (MRSI) to predict the oligodendroglioma grade.
  • METHODS: Twenty-four patients with pathologically confirmed oligodendrogliomas underwent dynamic contrast-enhanced perfusion-weighted magnetic resonance imaging and/or proton MRSI before surgery.
  • We assessed the ability of tumor contrast enhancement, normalized cerebral blood volume, normalized choline, and the presence of either lactate or lipid metabolites to correctly predict the World Health Organization tumor grade.
  • The accuracy of tumor grading using each method was also compared.
  • RESULTS: Tumor contrast enhancement (P = 0.069) and normalized cerebral blood volume (P = 0.181) were not significantly different between low and high-grade oligodendrogliomas.
  • The MRSI measurement of normalized choline was significantly higher in high-grade (2.82 +/- 0.64) than in low-grade (1.62 +/- 0.46) oligodendrogliomas (P < 0.001), and the presence of lactate or lipid metabolites also correctly predicted high-grade tumors (P = 0.014).
  • The maximum accuracy of contrast enhancement, normalized cerebral blood volume, normalized choline, and lactate or lipid metabolites in grading oligodendroglioma was 71, 83, 90, and 85%, respectively.
  • CONCLUSION: MRSI measurements are more accurate than perfusion-weighted magnetic resonance imaging or conventional contrast enhancement in differentiating oligodendroglial tumor grade.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Oligodendroglioma / diagnosis. Oligodendroglioma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Observer Variation. Preoperative Care. Reproducibility of Results. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854239.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. Miller CR, Dunham CP, Scheithauer BW, Perry A: Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol; 2006 Dec 1;24(34):5419-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.
  • PURPOSE: High-grade gliomas (HGGs; WHO grades 3-4) are highly diverse, with survival times ranging from months to years.
  • WHO 2000 grading criteria for high-grade oligodendroglial neoplasms [anaplastic oligoastrocytoma (AOA) and anaplastic oligodendroglioma (AO)] remain subjective, and the existence of grade 4 variants is controversial.
  • PATIENTS AND METHODS: Overall survival (OS) of 1,093 adult patients with a cerebral HGG newly diagnosed between 1990 and 2005 was analyzed by univariate and multivariate models for significance of the following factors: patient age, surgery type, year of diagnosis, endothelial proliferation, necrosis, oligodendroglial histology, treatment center, and chromosome 1p, 19q, 7p (EGFR), and 10q (PTEN) abnormalities by fluorescence in situ hybridization (FISH).
  • In addition to patient age, the following were significant independent prognostic factors (P .001): grade and surgery type for the entire HGG cohort; modified grade for AOA (3 v 4); and modified grade, 1p/19q codeletion status, and oligodendroglial histology for the 586 HGGs analyzed by FISH.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Oligodendroglioma / genetics. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Models, Statistical. Multivariate Analysis. Necrosis. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17135643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32CA009547
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


98. Kuroki K, Sugiyama K, Taguchi H, Yukawa O, Kurokawa M, Kajiwara Y, Usui S, Kurisu K: [Gliomatosis cerebri. Report of two cases]. No Shinkei Geka; 2006 May;34(5):513-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomatosis cerebri is a rare tumor of the central nervous system, and here we report two cases of this tumor.
  • The patient was diagnosed with gliomatosis cerebri, and surgery and whole brain radiation at 44Gy were performed.
  • A specimen obtained by open biopsy revealed anaplastic oligodendroglioma, which was diagnosed as gliomatosis cerebri.
  • Radiation at 54Gy, chemotherapy (ACNU, vincristine) and gamma-knife surgery were performed, and two months later MR imaging showed that the tumor (including the ringed enhanced lesion) had shrunk markedly.
  • [MeSH-major] Brain Neoplasms / diagnosis. Neoplasms, Neuroepithelial / diagnosis. Oligodendroglioma / diagnosis
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16689395.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


99. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M: Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res; 2005 Feb 1;11(3):1119-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
  • PURPOSE: Allelic loss at 1p is seen in 70% to 85% of oligodendrogliomas (typically in association with 19q allelic loss) and 20-30% of astrocytomas.
  • Because most 1p deletions in gliomas involve almost the entire chromosome arm, narrowing the region of the putative tumor suppressor gene has been difficult.
  • The latter group included both low-grade tumors (oligodendroglioma, diffuse astrocytoma, and "oligoastrocytoma") and high-grade tumors (anaplastic oligodendrogliomas, anaplastic astrocytomas, anaplastic oligoastrocytomas).
  • RESULTS: Allelic losses on 1p and 19q, either separately or combined, were more common in classic oligodendrogliomas than in either astrocytomas or oligoastrocytomas (P < 0.0001).
  • Classic oligodendrogliomas showed 1p loss in 35 of 42 (83%) cases, 19q loss in 28 of 39 (72%), and these were combined in 27 of 39 (69%) cases.
  • There was no significant difference in 1p/19q LOH status between low-grade and anaplastic oligodendrogliomas.
  • Although rare, 1p deletions were more often segmental in astrocytomas (5 of 6, 83%) than in oligodendrogliomas (3 of 35, 9%; P = 0.006).
  • Eleven tumors (6 oligodendrogliomas or having oligodendroglial components, 5 purely astrocytic) with small segmental 1p losses underwent further detailed LOH mapping.
  • All informative tumors in the oligodendroglial group and 2 of 3 informative astrocytomas showed LOH at 1p36.23, with a 150-kb MDR located between D1S2694 and D1S2666, entirely within the CAMTA1 transcription factor gene.
  • CAMTA1 is normally expressed predominantly in non-neoplastic adult brain tissue.
  • Relative to the latter, the expression level of CAMTA1 was low in oligodendroglial tumors and was further halved in cases with 1p deletion compared with those without 1p deletion (Mann-Whitney, P = 0.03).
  • CONCLUSIONS: Our data confirm the strong association of combined 1p/19q loss with classic oligodendroglioma histology and identify a very small segment of 1p36 located within CAMTA1 that was deleted in all oligodendroglial tumors with 1p LOH.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Glioma / genetics. Loss of Heterozygosity
  • [MeSH-minor] Adult. Astrocytoma / genetics. Astrocytoma / pathology. Calcium-Binding Proteins / genetics. Chromosome Deletion. Chromosome Mapping. Expressed Sequence Tags. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Microsatellite Repeats. Mutation. Oligodendroglioma / genetics. Oligodendroglioma / pathology. Reverse Transcriptase Polymerase Chain Reaction. Trans-Activators / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709179.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CAMTA1 protein, human; 0 / Calcium-Binding Proteins; 0 / Trans-Activators
  •  go-up   go-down


100. Xiong J, Liu Y, Wang Y, Ke RH, Mao Y, Ye ZR: Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas. Chin Med J (Engl); 2010 Dec;123(24):3566-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
  • BACKGROUND: Our previous study confirmed that oligodendrogliomas had higher frequency of chromosome 1p/19q deletion.
  • In order to improve the diagnostic criteria and to predict the prognosis of oligodendroglioma patients, the status of chromosome 1p/19q deletion, the methylation of O(6)-methylguanine-DNA methyltransferase (MGMT), and the expression of p53 protein were evaluated and investigated in relation to patients' outcomes.
  • RESULTS: Both oligodendrogliomas and astrocytic gliomas exhibited frequent methylation of MGMT.
  • The expression of p53 protein was more frequently observed in patients without a 1p or 19q deletion in anaplastic oligodendrogliomas (P = 0.032, 0.025).
  • In low-grade oligodendrogliomas, methylation of MGMT was more frequent in patients with 1p/19q deletion than in patients with 1p/19q intact (P = 0.038).
  • Patients with oligodendrogliomas with 1p/19q loss of heterozygosity and p53-negative showed a longer progression-free survival.
  • CONCLUSION: Detection of chromosome 1p/19q status combined with p53 protein immunohistochemistry might be beneficial to improve the pathological diagnosis and to determine the prognosis of patients with oligodendrogliomas.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Deletion. Chromosomes, Human, Pair 19. Oligodendroglioma / genetics. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Child. Chromosomes, Human, Pair 1. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Disease-Free Survival. Female. Gene Expression Regulation, Neoplastic. Humans. Loss of Heterozygosity. Male. Middle Aged. Prognosis. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22166632.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; Chromosome 1, monosomy 1p
  •  go-up   go-down






Advertisement